PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETIC 
INTERACTIONS BETWEEN PF-06882961 AND PF-06865571 IN HEALTHY ADULT 
PARTICIPANTS (PART A) AND OVERWEIGHT ADULTS OR ADULTS WITH 
OBESITY WHO ARE OTHERWISE HEALTHY (PART B)
Study Intervention Number: PF-06882961 and PF-06865571
Study Intervention Name: N/A
US IND Number:
EudraCT Number: N/A
Protocol Number: C3421038
Phase: 1
Short Title: A Phase 1 Study to Evaluate the Pharmacokinetic Interactions Between
PF-06882961 and PF-06865571
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must
be promptly notified.
CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Protocol Amendment 
#203 June 2021 Section 1 –Protocol Summary  –Objectives 
and Endpoints, Schedule of Activities –
PartB
, Section [IP_ADDRESS].1 – Clinical 
Pharmacokinetics of PF -
06882961, Section 3 
–Objectives and Endpoints, Section 4.2 
–
Scientific Rationale for Study  Design, 
Section 8.8 Biomarkers , Section 9.4 –
Statistical Analy ses: Added plasma CP -I and 
4-β-hydroxycholesterol/cholesterol 
assessments at specified timepoin
ts in Part B 
and updated the background, study  rationale, 
objectives/endpoints, assessments/procedures 
and statistical anal yses as appropriate.
Rationale: Preliminary  draft data from 
study C3421007 indicate that a decrease 
in exposure of midazolam are observed 
when co -administered with 
PF-06882961.  To investigate the 
mechanism of this interaction, 
assessment of plasma 
4-β-hydroxycholesterol/cholesterol, an 
endogenous probe for CYP3A 
induct
ion, is being added in Part B.
In vitro studies indic ate PF -06882961 
may inhibit OATP1B1 at dose(s) 
evaluated in this study .  Therefore, to 
evaluate this potential effect of 
PF-06882961, measurement of plasma 
CP-I, an endogenous probe for OATP1B 
activity , is being added in Part B.
Schedule of Activities Part B, Section 4.2 –
Scientific Rationale for Study  Design, 
Table 14 – Protocol Required Safet y 
Laboratory  Assessments : Added Cy statin -C 
sampling at baseline and subsequent safet y 
laboratory  assessments.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 3Rationale: PF -06865571 is a 
dose-dependent inhibitor of the 
transporters OCT2/MATE in the kidney .  
As expected, increases in serum 
creatinine without a change in renal 
function (as assessed via eGFR 
determined using Cy statin -C) have been 
noted in prior stu dies.  This interaction 
interferes with accurate monitoring of 
renal function with serum creatinine; 
therefore, C ystatin-C sampling is being 
introduced for Part B to enable accurate 
monitoring of renal function as part of 
safet y assessments during repeated
co-administration of PF -06865571 and 
PF-06882961.
Section [IP_ADDRESS].1 – Clinical and Safet y 
Experience with PF
-06882961: Added 
preliminary  safety  data from the C3421007 
study .
Rationale: The C3421007 preliminary  
data provides the most up -to-date 
clinical safet y data with PF -06882961.
Section 5.4 – Screen Failures: Modified 
rescreening criteria to clarify thatrepeating of 
screening procedures and reassignment of 
new identification number is not required in 
the event of unexpected delay s as long as 
laborato
ry results obtained prior to first dose 
administration meet eligibility  criteria.
Rationale: This was an inadvertent 
inconsistency  between rescreening 
language in Section 5.4 –Screen 
Failures and Section 8 –Study  
Assessments and Procedures.  Updated 
language allows for flexible rescreening 
procedures within a healthy volunteer 
population.
Section 8 – Study  Assessments and 
Procedures: Modified blood sampling volume 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 4from 400 mL  rounded up to 525 mL for 
PartB.
Rationale: Cy statin -C assessments 
require an additional 55 mL  total blood 
sampling volume.   CP-I and 
4-β-hydroxycholesterol/choleste rol 
assessments require 
51mL and 1 6mL 
blood sampling volume, respectivel y.
Protocol Amendment 
#112 M arch 2021 Section 1.1 - Synopsis , Section 4.1.1 - PartA 
Study  Design; The duration of Part A is
approximately  9 weeks instead of 8 weeks.
Rationale: This was an inadvertent 
miscalculation of the number of weeks 
within the study  timeline in FAP.
Section 1.1 - Synopsis, Section 3 -Objectives 
and Endpoint s:Included “Assessment of 
mental health as determined by  C
-SSRS and 
PHQ -9 in Part B of the study ”as secondary  
endpoint in Part B.
Rationale: This was an inadvertent 
exclusion in FAP.
Schedule of Activities Part A: Remove
d‘X’ 
from ‘Inpatient stay  at CRU’ row for the 
ET/DC visit .
Rationale: Table is now consistent with 
theSchedule of Activities in Part B. 
The Earl y Termination/Discontinuation 
visit is considered out -patient and does 
not require an overnight inpatient stay .
Schedule of Activities Part A: Ensured
footn
otes for Day  -1 activities were 
footnote ‘e’“If participant is not discharged 
from the CRU between Periods 1 and 2, 
procedure onl y needs to be conducted in 
Period 1 only .”

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 5Rationale: Error during protocol 
amendment formatting/finalization.
Schedule of Activities Part A/B, Section 
4.2 - Scientific Rationale for Study Design, Section 8, Study Assessments and Procedures,  
 
 
 
 
Rationale: Updated terminology with 
new protocol/ICD templates.
Schedule of Activities Part A/B, 
Appendix 2-Clinical Laboratory Tests: Removed HepBsAb and HepBcAb from Screening testing.
Rationale: Removal ensures consistency 
with Exclusion Criteria #27 and C3421007 eligibility criteria. Sampling was confirmed not to be necessary for determination of viral exclusionary status.
Section 5.2-Exclusion Criteria #2: Removed 
appendectomy from list of any condition possibly affecting drug absorption.
Rationale: It was determined that 
appendectomy would not affect drug absorption and its inclusion was an oversight.
Section 5.2-Exclusion Criteria #19: Added 
language that an emergency use authorized or approved COVID-19 vaccine is considered a concomitant medication.CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 6Rationale: Included COVID -19 vaccine 
language in clinical studies as per FDA 
guidance.
Section 5.2- Exclusion Criteria # 27: Modified 
and added additional abnormalities in clinical 
laboratory  tests, including ALT/AST, total 
bilirubin, TSH, fasting trigl yceride, INR, and 
PLT.
Rationale: FDA correspondence from 
IND submission.
Section 10.1.7 - Source Documents :Added 
language for data t
ypes that may be recorded 
directly  on the CRFs (ie, for which there is no 
existing written or electronic record of data) 
and is to be considered data source.
Rationale: Allow for direct data capture 
CRF input, reducing the amount of data 
transcribed from paper source 
documents to improve efficiency  and 
data quality .
Section 6.7 - Stoppi[INVESTIGATOR_1869]: Added s ection 
and sub
-section 6.7.1-6.7.3 to call out 
stoppi[INVESTIGATOR_774313], 
develop
ment of adverse events, and 
individual participant development of adverse 
events.
Rationale: FDA corresponde ncefrom 
IND submission.
Section 9.4.3 - Safet y Analyses : Continuous 
cardiac 
monitoring removed from items to be 
reviewed and summarized.
Rationale: This was an inadvertent 
exclusion in FAP. Continuous cardiac 
monitoring/telemetry  was never being 
performed in this study .
Section [IP_ADDRESS] - Electrocardiogram Analy ses: 
Added sentence that exposure -QT anal yses is 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 7performed, it will be reported separatel y, not 
as part of the CSR.
Rationale: Clarifcation as requested .
Appendix 1, Section 10.1.3 -Informed 
Consent Process: Removed last paragraph in 
section describing consent for optional 
additional research.
Rationale: Removed as per new 
ICD/protoc ol template guidance and 
language.
Appendix 4, Section 10.4.3 -Woman of 
Childbearing Potential, 
Section 10.4.4 - Contrace ption Methods: Use 
of hormonal contraception by  [CONTACT_774326].
Rationale: Per study  team discussion, 
use of hormonal contraception has been 
removed from this study  to ensure no 
possible drug- drug interactions with 
study  interventions and to maintain
consistency  with Section 6.5.
Appendix 9 ,Alternative Measures During 
Public Emergen cies: Added this appendix .
Rationale: Includes new template 
content, 
re-affirming COVID -19 testing 
eligibility  and COVID -19 safet y 
reporting.
Other m inor spelling errors and 
inconsistencies corrected/modified throughout 
protocol to ensure accuracy  and improved 
trial conduct.
Original protocol 23December 
2020N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs.

PF-[ADDRESS_1063435] OF TABLES ................................ ................................ ................................ ................... 13
1. PROTOCOL  SUMMARY ...................................................................................................15
1.1. Sy nopsis ..................................................................................................................15
1.2. Schema ....................................................................................................................17
1.2.1. Treatment Scheme for Part A
.....................................................................17
1.2.2. Treatment Scheme for Part B
.....................................................................17
1.3. Schedule of Activities .............................................................................................18
1.3.1. Schedule of Activities for Part A ................................................................18
1.3.2. Schedule of Activities for Part B ................................................................20
2. INTRODUCTION ...............................................................................................................24
2.1. Study  Rationale .......................................................................................................24
2.2. Background .............................................................................................................24
2.2.1. Non
-Alcoholic Steatohepatitis ....................................................................24
2.2.2. Nonclinical Pharmacokinetics ....................................................................25
[IP_ADDRESS]. Nonclinical Pharmacokinetics and Metabolism of PF -
06882961
...........................................................................................25
[IP_ADDRESS]. Nonclinical Pharmacokinetics and Metabolism of PF -
06865571 ...........................................................................................26
2.2.3. Nonclinical Toxicology ..............................................................................26
[IP_ADDRESS]. Summary  of Toxicology  Studies with PF -
06882961................26
[IP_ADDRESS]. Summary  of Toxicology  Studies with PF -
06865571................27
[IP_ADDRESS]. Summary  of Toxicology  Study  for Co -administ
ration of 
PF-06882961 and PF- 06865571 ........................................................27
2.2.4. Clinical Overview .......................................................................................27
[IP_ADDRESS]. Summary  of Clinical Safet y
......................................................27
[IP_ADDRESS]. Summary  of Clinical Pharmacology  and Biopharmaceutic 
Studies ...............................................................................................29
2.3. Benefit/Risk Assessment
.........................................................................................30
2.3.1. Risk Assessment
.........................................................................................31
2.3.2. Benefit Assessment .....................................................................................35
2.3.3. Overall Benefit/Risk Conclusion ................................ ................................ 35

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 93. OBJECTIVES AND EN DPOINTS .....................................................................................36
4. STUDY DESIGN .................................................................................................................37
4.1. Overall Design .........................................................................................................37
4.1.1. Part A Study  Design ...................................................................................37
4.1.2. Part B Study  Design ....................................................................................38
4.2. Scientific Rationale for Study  Design .....................................................................38
4.3. Justification for Dose ..............................................................................................41
4.3.1. PF -
06882961...............................................................................................41
[IP_ADDRESS]. PF -
06882961 in Part A ..............................................................41
[IP_ADDRESS]. PF -
06882961 in Part B..............................................................41
4.3.2. PF -06865571 in Part A and Part B .............................................................42
4.4. End of Study  Definition ..........................................................................................42
5. STUDY POPUL ATION
......................................................................................................42
5.1. I nclusion Criteria .....................................................................................................43
5.2. Exclusion Criteria ....................................................................................................43
5.3. L ifesty le Considerations ..........................................................................................47
5.3.1. Meals and Dietary  Restrictions ...................................................................47
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................48
5.3.3. Activity .......................................................................................................48
5.3.4. Contraception ..............................................................................................49
5.4. Screen Failures ........................................................................................................49
6. STUDY INT
ERVENTION ..................................................................................................49
6.1. Study  Intervention(s) Administered ........................................................................49
6.1.1. Administration ............................................................................................50
6.2. Preparation/Handling/Storage/Accountability ........................................................51
6.2.1. Preparation and Dispensing ........................................................................52
6.3. Measures to Minimize Bias: Randomization and Blinding ................................ .....52
6.3.1. Allocation to Study Intervention ................................ ................................ 52
6.4. Study  Intervention Compliance ...............................................................................54
6.5. Concomitant Therapy ..............................................................................................54
6.5.1. Rescue Medicine .........................................................................................55

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. M anagement of Nausea and Vomiting ......................................55
6.6. Dose Modification ...................................................................................................55
6.7. Stoppi[INVESTIGATOR_1869]
........................................................................................................55
6.7.1. Partici pant Death ........................................................................................55
6.7.2. I ndividual Participant Development of Adverse Events (Part B onl y).......56
6.7.3. Cohort L evel Assessment of Adverse Events (Part B, Period 4 onl y).......56
6.8. I ntervention After the End of the Study ..................................................................56
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................57
7.1. Discontinuation of Study  Intervention ....................................................................57
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1063436] to Follow up
....................................................................................................58
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................59
8.1. Efficacy  Assessments ..............................................................................................60
8.2. Safet y Assessments .................................................................................................60
8.2.1. Phy sical Examinations ................................................................................60
8.2.2. Vital Signs ..................................................................................................61
8.2.3. Electrocardiograms
.....................................................................................62
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................63
8.2.5. Suicidal I deation and Behavior Risk Monitoring .......................................63
[IP_ADDRESS]. Columbia Suicide Severit y Rating Scale (Part B onl y).............63
[IP_ADDRESS]. Patient Health Questionnaire
-9 (Part B only ) ...........................64
[IP_ADDRESS]. Referral to a Mental Health Professional ..................................64
8.2.6. COVID -
19 Specific Assessments................................ ............................... 65
8.2.7. Pregnancy  Testing ......................................................................................65
8.2.8. Management of Hy pogly cemia ...................................................................65
[IP_ADDRESS]. Definition and Severit y of Categorization of 
Hypoglycemic Adverse Event (HAE) ...............................................65
8.2.9. Glucometer Monitoring of Glucose
............................................................67
8.3. Adverse Events and Serious Adverse Events
..........................................................67
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......67

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................68
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................68
8.3.2. Method of Detecting AEs and SAEs ..........................................................688.3.3. Follow-up of AEs and SAEs.......................................................................688.3.4. Regulatory Reporting Requirements for SAEs...........................................698.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................69
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................71
8.3.6. Cardiovascular and Death Events...............................................................728.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_1063437].............................................................72
[IP_ADDRESS]. Lack of Efficacy........................................................................72
8.3.9. Medical Device Deficiencies......................................................................728.3.10. Medication Errors .....................................................................................72
8.4. Treatment of Overdose............................................................................................738.5. Pharmacokinetics ....................................................................................................74
8.5.1. Plasma for Analysis of PF-06882961 .......758.5.2. Plasma for Analysis of PF-06865571.........................................................75
8.6. Pharmaco dynamics..................................................................................................75
8.8. Biomarkers ..............................................................................................................76
8.8.5. Plasma for Analysis of CP-I (Part B only) .................................................76CCI
CCICCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 128.8.6. Plasma for 4-β- hydroxy cholesterol/cholesterol Analy sis (Part B 
only) ................................ ................................ ................................ ................. 76
8.9. I mmunogenicit y Assessments .................................................................................77
8.10. Health Economics .................................................................................................77
9. STATI STICAL CONSI DERATIONS
................................................................................77
9.1. Statistical Hy potheses .............................................................................................77
9.2. Sample Size Determination .....................................................................................77
9.2.1. Sample Size for Part A
...............................................................................77
9.2.2. Sample Size for Part B
................................................................................78
9.3.Analy sis Sets ...........................................................................................................79
9.4. Statistical Analy ses.................................................................................................79
9.4.1. General Considerations ...............................................................................79
[IP_ADDRESS]. Derivation of Pharmacokinetic and Endogenous 
Biomarker Parameters .......................................................................79
9.4.2. Statistical Methods for Pharmacokinetic Data
...........................................81
[IP_ADDRESS]. Part A 
–Statistical Methods for Pharmacokinetic Data ............81
[IP_ADDRESS]. Part B 
–Statistical Methods for Pharmacokinetic and 
Endogenous Biomarker Data .............................................................82
9.4.3. Safet y Anal yses..........................................................................................83
[IP_ADDRESS]. Electrocardiogram Analy ses......................................................83
9.4.4. Other Anal yses............................................................................................83
9.5. I nterim Anal yses.....................................................................................................84
9.6. Data Monitoring Committee or Other Independent Oversight Committee .............84
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................85
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............85
10.1.1. Regulatory and Ethical Considerations ....................................................85
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................85
10.1.2. Financial Disclosure ................................ ................................ ................. 86
10.1.3. I nformed Consent Process ........................................................................86
10.1.4. Data Protection .........................................................................................87
10.1.5. Dissemination of Clinical Study  Data ......................................................87

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 1310.1.6. Data Qualit y Assurance ............................................................................88
10.1.7. Source Documents....................................................................................8910.1.8. Study and Site Start and Closure ..............................................................9010.1.9. Publication Policy.....................................................................................9110.1.10. Sponsor’s Qualified Medical Personnel .................................................92
10.2. Appendix 2: Clinical Laboratory Tests .................................................................9310.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................95
10.3.1. Definition of AE .......................................................................................9510.3.2. Definition of SAE.....................................................................................9610.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................9710.3.4. Reporting of SAEs..................................................................................100
10.4. Appendix 4: Contraceptive Guidance .................................................................102
10.4.1. Male Participant Reproductive Inclusion Criteria ..................................[ZIP_CODE].4.2. Female Participant Reproductive Inclusion Criteria...............................[ZIP_CODE].4.3. Woman of Childbearing Potential ..........................................................[ZIP_CODE].4.4. Contraception Methods...........................................................................103
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ......106
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................[ZIP_CODE].8. Appendix 8: Proposed Chronology of Procedures..............................................[ZIP_CODE].9. Appendix 9: Alternative Measures During Public Emergencies ........................111
10.9.1. Eligibility ................................................................................................[ZIP_CODE].9.2. Adverse Events and Serious Adverse Events .........................................111
10.10. Appendix 10: Abbreviations .............................................................................[ADDRESS_1063438] OF TABLES
Table 1. Part A – Overall Schedule of Activities ...................................................18Table 2. Part B – Overall Schedule of Activities....................................................20Table 3. Part B – Schedule of Activities for:..........................................................23
Table 4. Part A Dosing ...........................................................................................50CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 14Table 5. Part B Dosing............................................................................................50
Table 6. Part A Sequence 1 – Dosing Regimens for PF-06882961 and PF-
06865571 ..................................................................................................52
Table 7. Part A Sequence 2 – Dosing Regimens for PF-06882961 and PF-
06865571 ..................................................................................................53
Table 8. Part B – Dosing Regimens for PF-[ADDRESS_1063439] of PF-06865571 on PF-06882961 in Part A –
Expected Widths of the 90% CIs (with 80% Coverage Probability)for Different Possible Estimated Effects and Parameters of Interest .......[ADDRESS_1063440] of PF-06865571 on PF-06882961 in Part B –
Expected Widths of the 90% CIs (with 80% Coverage Probability) for Different Possible Estimated Effects and Parameters of Interest .......[ADDRESS_1063441] of PF-06882961 on PF-06865571 in Part B –
Expected Widths of the 90% CIs (with 80% Coverage Probability) for Different Possible Estimated Effects and Parameters of Interest .......78
Table 12. Part A – Plasma PK Parameters for PF-06882961 ...................................80Table 13. Part B – Plasma PK Parameters for PF-06882961
and PF-06865571, and Plasma CP-I Parameters ......................................80
Table 14. Protocol Required Safety Laboratory Assessments..................................93
CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 151.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: A Phase 1 Study  to Evaluate the Pharmacokinetic Interactions Between 
PF-06882961 and PF- 06865571
Rationale :This study  will evaluate the PK interactions between PF -06882961 and 
PF-
06865571 in health y adult participants (Part A) and overweight adults or adults with 
obesity who are otherwise healthy  (Part B).
Objectives and Endpoints:
Objectives Endpoints
Part A
Primary: Primary: 
To evaluate the effects of PF -06865571 on the single -
dose pharmacokinetics of PF-06882961 in healthy 
adult participants.PF-06882961 plasma pharmacokinetic parameters: 
Cmaxand AUC 24.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-06882961 alone and in combination with 
PF-06886571 when administered to healthy adult 
participants.Assessment of treatment-em ergent adverse events, 
clinical laboratory abnormalities , vital signs, body 
weight, and ECG parameters during the entire study.
Tertiary/Exploratory: Tertiary/Exploratory: 
To evaluate the effects of PF -06865571 on additional 
pharmacokinetic parameters of PF-06882961 in 
healthy adult participants.Additional PF -06882961 plasma pharmacokinetic 
parameters: Tmax.
Part B
Primary: Primary: 
 To evaluate the effects of PF -06882961 on the 
single -dose pharmacokinetics of PF-06865571 in 
overweight adults or adults with obesity who are 
otherwise healthy. PF-06865571 plasma pharmacokinetic parameters on 
Day 1 and Day 47: Cmax, AUC last, and AUC inf,as 
data permits.
 To evaluate the effects of PF -06865571 on the 
multiple -dose pharmacokinetics of PF-06882961 in 
overweight adults or adults with obesity who are 
otherwise healthy. PF-06882961 plasma pharmacokinetic parameters on 
Day 46 and Day 61: Cmaxand AUC 12.
Secondary: Secondary: 
 To evaluate the safety and tolerability of 
PF-06882961 and PF -06865571 when administered 
separately and in combination in overweight adults or 
adults with obesity who are otherwise healthy. Assessment of treatment-em ergent adverse events, 
clinical laboratory abnormalities , vital signs, body 
weight, and ECG parameters during the entire study.
 Assessment of mental health as determined by 
C-SSRS and PHQ -9 in Part B of this study.
Tertiary/Exploratory: Tertiary/Exploratory: 
 To evaluate the effects of PF -06882961 on additional 
pharmacokinetic parameters of PF-06865571 in 
overweight adults or adults with obesity who are 
otherwise healthy. Additional PF -06865571 plasma pharmacokinetic 
parameters on Day 1 and Day 47: Tmax, CL/F, Vz/F, 
and t ½, as data permits.

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 16• To evaluate the effects of PF-06865571 on additional 
pharmacokinetic parameters of PF-06882961 in 
overweight adults or adults with obesity who are 
otherwise healthy.• Additional PF-06882961 plasma pharmacokinetic 
parameters on Day 46 and Day 61: T maxand CL/F.
• To evaluate the effects of PF-06882961 on the 
multiple-dose pharmacokinetics of PF-06865571 in overweight adults or adults with obesity who are 
otherwise healthy.• PF-06865571 plasma pharmacokinetic parameters on 
Day 61: 
Cmax, Tmax, and AUC 12.
• To evaluate the effects of multiple doses of 
PF-06882961 on CYP3A induction in overweight 
adults or adults with obesity who are otherwise 
healthy.• Morning pre-dose 4- β-hydroxycholesterol/cholesterol 
plasma ratio on Days 1, 19, 31, and 47.
• To evaluate the effect of multiple doses of 
PF-06882961 on CP-I in overweight adults or adults with obesity who are otherwise healthy.• CP-I parameters on Days 30 and 46: AUC
12and C max.
Overall Design: This study will be conducted in [ADDRESS_1063442] of PF-06882961 on PF-06865571 PK will be evaluated at steady-state 200 mg BID doses of PF-06882961. Then, PF-06882961 and PF-06865571 will be coadministered for approximately 2 weeks for further evaluation of PK interactions and to generate additional safety and tolerability data on the combination.
Number of Participants: A cohort of approximately 8 participants will be enrolled in 
Part A. Approximately 16 participants will be enrolled in Part B such that approximately 12 evaluable participants complete Part B.
Intervention Groups and Duration: The study interventions in this study are PF-06882961 
and PF-06865571. Both will be administered as tablets for oral administration. In Part A, each participant will receive a single dose of PF-06882961 in 1 period and co-administration of PF-06882961 and PF-06865571 in another period. The duration of Part A will beapproximately 9 weeks. In Part B, each participant will receive PF-06865571 alone, PF-06882961 alone, and co-administration of PF-06865571 and PF-06882961. The duration of Part B will be approximately 18 weeks.
Data Monitoring Committee or Other Independent Oversight Committee: NoStatistical Methods: In Part A, natural log-transformed C
maxand AUC 24of PF-[ADDRESS_1063443], and AUC inf(as data permit) of PF -[ADDRESS_1063444]. All safet y data will be summarized descriptively  through 
appropriate data tabulation, descriptive statistics, categorical summaries, and graphical 
presentations .
1.2.Schema
1.2.1. Treatment Scheme for Part A
Period 1 Washout* Period 2
Sequence 1
(n=4)Treatment A:
[ADDRESS_1063445] 3days*Treatment B:
20 mg PF -06882961 single dose
plus
300 mg PF -06865571 single dose
Sequence 2
(n=4)Treatment B:
[ADDRESS_1063446] 3days*Treatment A:
20 mg PF-06882961 single dose
*Each participant is planned to undergo [ADDRESS_1063447] 3days following the final dose of study intervention administered in Period 1. 
1.2.2. Treatment Scheme for Part B
Period 1 Period 2 Period 3 Period 4
Days 1-2 Days 3-46 Days 4 7-48 Days 49-62
PF-06865571
(DGAT2)
Dose300 mg single dose 
on Day 1 onlya N/A300 mg single dose 
on Day 4 7onlya300 mg BID 
on Days 49-61a
PF-06882961
(GLP -1)
DoseN/A10 mg BID titrated 
to 200 mg BIDb,c 200 mg BIDc 200 mg BID 
on Days 49-61b,c
a. Dense PK sampling for measurement of PF -06865571 plasma concentrations on Day 1 (reference), Day 
47(test) , and Day 61 (summary statistics only) .
b.Dense PK sampling for measurement of PF -06882961 plasma concentrations on Day 46 (reference ) and 
Day 61(test) .
c.Doses of PF-06882961 may be reduced based on PK results of Part A of this study and safety and 
tolerability results of Study C3421007.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 181.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protec t thewell-being of the participant .
1.3.1. Schedule of Activities for Part A
Table 1. Part A –Overall Schedule of Activities
Visit Identifiera Screen
Day -28 to -2Periods 1 and 2b
ET/DC F/Uc
Day -1 Day 1 Day 2
Hours After Dose 0 0.5 1 2 3 4 6 8 10 12 16 24
Informed consent & demography X
Outpatient visit (after ≥[ADDRESS_1063448]) X
COVID -19 questionnairedX Xe
COVID -19 testingfX X
COVID -19 temperature checkgX X XhX X
Inpatient stay at CRU X            Xi
Assessment of eligibility (with update on Day -1 in 
Period 1 only)X X
Medical and medication history X Xe
Review alcohol, tobacco, and drug use X Xe
Review prior or concomitant treatments X             X X X
Serious and non -serious adverse event monitoring X             X X X
Physical examination (height and body weight at 
Screening only)j XjXj
Review contraception use X XeX X X
Single supi[INVESTIGATOR_050] [ADDRESS_1063449] meals/ snackslX XhX X
Blood samples for:
Safety laboratory tests X X X X

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 19Visit Identifiera Screen
Day -28 to -2Periods 1 and 2b
ET/DC F/Uc
Day -1 Day 1 Day 2
Hours After Dose 0 0.5 1 2 3 4 6 8 10 12 16 24
FSHmX
Serum pregnancy testmXXe
HIV, HepBsAg, HCVAb, HCV RNA testing X
PF-06882961 PK XhX XXXXXX XXX X X
Urine samples for:
Urine drug screening X Xe,o
Urinalysis (and microscopy if needed) X X X X
a. Day relative to start of study treatment (Day 1).
b. There will be a washout interval of at least [ADDRESS_1063450] will be performed after 4 days 
(ie, upon completion of 4 x 24 hours in house if not discharged between  periods), or if participant develops COVID-[ADDRESS_1063451] daily during residence.h. Prior to dosing. i. Discharge from CRU; participants may be confined to the CRU after completion of Day 2 activities in Period 1 at the discretion of the investigator. 
j. Complete physical examination to be conducted upon admission of Period 1 only. Brief physical examinations may be performed as appropriate at other times at the 
investigator’s discretion or if there are findings during the previous examination or new/open AEs. Height and weight to be measu red at Screening only.
k. Only for the period with Treatment B.l. While inpatient, meals to be provided at clock times matching nominal times of approximately 0H (breakfast), 4H (lunch), and 10H ( dinner); snacks may be provided 
according to Section 5.3.1 .
m. Testing in females only: Serum β-hCG for all WOCBP; FSH for female participants to confirm post-menopausal status only.
o. A urine drug test is to be completed for both periods of this study unless participant is not discharged between periods. In ad ditiona. ad hoc urine drug testing may be 
conducted throughout the study at the discretion of the investigator.CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 201.3.2. Schedule of Activities for Part B
Table 2. Part B – Overall Schedule of Activities
Visit Identifier ScreenPeriod 1
(PF-06865571 Only)Period 2
(PF-06882961 Only)Period 3
(PF-06865571 plus 
PF-06882961)Period 4
(PF-06865571 plus 
PF-06882961)F/U
VisitaF/U 
Contact[CONTACT_774327]/DC
Day in Study Periodb-28 to -2 -1 1 2 1 2 3-43 44 1 2 1-12 13 14 - - -
Days in S tudyc-28 to -2 -1 1 2 3 4 5-45 46 47 48 49-60 61 62 68-71 89-96 -
Informed consent & demography X
Outpatient visit (after ≥[ADDRESS_1063452]) X X
COVID -19 questionnairedX X
COVID -19 testingeX X Xe
COVID -19 temperature checkfX X X X X X XfX X X XfX X X X
Inpatient stay at CRU X           Xg
Eligibility criteria X X
Medical and medication history X X
C-SSRS and PHQ -9 X X XhXhX X X
Review drug, alcohol/tobacco use X X X
Review contraception use X X X X X
Review prior or concomitant treatments X X           X X X X
Serious and nonserious AE monitoring X X           X X X X
Standardized meals/snacksiX           X
Physical exam (height at Screen only)jXjXj
Body weight X XhXhX X X
Supi[INVESTIGATOR_050] 12 -lead ECG X XkXhXhX X X
Supi[INVESTIGATOR_774314] X XkXhXhX X X
PF-06882961 administrationl
Table 3X X X
Table 3
Table 3X X
Table 3PF-06865571 administrationlX
Blood samples for:
Safety laboratory tests X X XhXhX X X
Cystatin-C X XhXhX X X
PT/INR/aPTT X X XmXmX X X
HIV, HepBsAg, HCVAb, HCV RNA
testingX
FSHnX
Serum pregnancy testnX X XoXo
TSH, lipi[INVESTIGATOR_805] X X XmXmX X X
Free T4, calcitonin, amylase, lipase, TBA X X XmXmX X X

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 21Visit Identifier ScreenPeriod 1
(PF-06865571 Only)Period 2
(PF-06882961 Only)Period 3
(PF-06865571 plus 
PF-06882961)Period 4
(PF-06865571 plus 
PF-06882961)F/U
VisitaF/U 
Contact[CONTACT_774327]/DC
Day in Study Periodb-28 to -2 -1 1 2 1 2 3-43 44 1 2 1-12 13 14 - - -
Days in Studyc-28 to -2 -1 1 2 3 4 5-45 46 47 48 49-60 61 62 68-71 89-96 -
HbA1c X
PF-06882961 PK X
PF-06865571 PK XpXqXpXqX
 
CP-I XsXsXs
4-β-hydroxycholesterol/cholesterol XtXtXt
Urine samples for:
Urine drug screeninguXX
Urinalysis (& microscopy as appropriate) X X XhXhXX X
a. The follow-up visit will occur 7-[ADDRESS_1063453] at each visit.
e. Testing for COVID-19 pathogen by [CONTACT_774328] 4 days (ie, upon completion of 4 x 24 hours in house), or if par ticipant develops COVID-[ADDRESS_1063454] daily during residence.g. Discharge from CRU.h. Assessments to be performed on Days 8, 15, 22, 29, 36, 43, 50, and 57.
i. Meals to be provided at clock times matching nominal times of approximately 0H (breakfast), 4H (lunch), and 10H (dinner), with t he exception Overall Study Day 46,
Day 47, and Day 61 in which dinner will be provided at approximately 12H; snacks may be provided according to Section 5.3.1 .
j. Complete physical examination to be conducted upon admission in Period 1. Brief physical examinations may be performed as appro priate at other times at the investigator’s 
discretion or if there are findings during the previous exam or new/open AEs. Height to be measured at Screening only.  
k. Prior to dosing.l. Dosing to occur BID immediately after breakfast and dinner as specified in Section 5.3.[ADDRESS_1063455]. On Overall Study 
Day 46, Day 47, and Day 61, evening doses will be administered immediately after dinner approximately 12 hours after morning dosing.  On all other study days, evening 
doses will be administered immediately after dinner approximately 10 hours after morning dosing.
m. Assessments to be performed on Days 15, 29, 43, and 57.
n. Testing in females only: Serum β-hCG for all WOCBP; FSH for female participants to confirm post-menopausal status only.
o. Serum pregnancy test to be conducted on Day 30 and Day 60.
p. PK sample to be collected 24 hours after Day 1 and Day 47 morning doses of PF-06865571. CCI CCICCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 22q. PK sample to be collected 48 hours after Day 1 and Day 47 morning doses of PF-06865571.
s. Samples to be collected at 0 (pre-dose), 12 and 24 hours after Day 1 morning dose of PF-06865571 and at 0 (pre-dose), 1, 2, 4 , 6, 8 and 12 hours after Day 30 and Day 46 
morning doses of PF-06882961.
t. Samples to be collected on Days 1, 19, 31, and 47 prior to morning dosing of study intervention(s).u. A urine drug test is to be conducted at Screening. In addition, participants may undergo ad hoc urine drug screening throughout the study at the discretion of the investigator.CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 23Table 3. Part B – Schedule of Activities for:
•Day 1 of Period 1 (PF-06865571 ONLY) – Study Day 1.
•Day 44 of Period 2 (PF-06882961 ONLY) – Study Day 46.
•Day 1 of Period 3 (PF-06865571 plus PF-06882961) – Study Day 47.
•Day 13 of Period 4 (PF-06865571 plus PF-06882961) – Study Day 61.
Hours Relative to Dosing at 0H 0 0.5 1 2 3 4 6 8 10 12 14 16
PF-06882961 administration (Periods 2, 3, and 4 only) XaXb
PF-06865571 administration (Periods 1, 3, and 4 only) XaXb,c
Blood sampling for: 
PF-06882961 PK (Periods 2 and 4 only; pre-dose in Period 3 onlyd)Xd,e,fXfXfXfXfXfXfXfXfXe,f
PF-06865571 PK (Periods 1, 3, and 4 only) XeX XXXXX X X XgXhXh
a. Dosing to occur immediately after breakfast.
b. Dosing to occur immediately after dinner.
c. Period 4 only.d. Only a predose sample will be collected on Day 1 of Period 3 (24 hours after morning dosing on Day 46 of Period 2; overall stu dy Day 47). The full dense sampling scheme, 
including the predose sample, will occur in Periods [ADDRESS_1063456] of the GL P-1 
receptor and is presently  in clinical development for the treatment of T2DM and obesity . 
PF-06865571 is a potent and selective inhibitor of DGAT2 being developed for the treatment 
of NASH with liver fibrosis. The current study  will evaluate PK interactions following 
coadministration of PF- 06882961 and PF -06865571 as a novel NCE:NCE combination 
because of the potential advantages offered b y the combination over the individual 
investigational agents that could benefit a wider NASH population and/or target specific 
NASH sub -populations. The safet y and tolerability of the investigational drugs admin istered 
together will also be assessed .
GLP
-1 is a neuroendocrine hormone that is predominantly  released from the small intestine 
in response to food intake .1GLP-1 activation of the GL P-1 receptor stimulates insulin 
release, inhibits glucagon secretion in a glucose- dependent manner, and delay s gastric 
empty ing.2,3In addition, GL P-1 has been shown to increase satiety and suppress food 
intake .4Administration of GLP-1 receptor agonists led to histological improvements in 
patients with NAFLD including resolution of NASH without worsening of fibrosis.5
DGAT scataly ze the terminal step in TG synthesis; specifically , the esterification of a fatty  
acid with diacy lglycerol
resulting in the formation of TG .6In mammals, 2 structurally  
unrelated DGAT enz ymes(DGAT1 and DGAT2) have been characterized. DGAT1 is 
highl y expressed in the intestine and play s a central role in fat absorption.7DGAT2 is highl y 
expressed in liver and adipose.8In preclinical models, blockade of hepatic DGAT2 using 
antisense oligonucleotides results in both down- regulation of the expression of multiple 
genes encoding proteins involved in lipogenesis and parallel induction in oxidative 
pathway s
.9-11The net result of these changes is a decrease in the levels of hepatic DAG and 
TG lipid which, in turn, reduces hepatocy te lipid burden and decreases hepatic very  low 
density  lipoprotein TG secretion.9,11Consistent with this, administration of DGAT2 
inhibitors to patients with NAFLD reduces steatosis,11,12a necessary but not sufficient 
component of the path ogenesis of NASH .13PF-06865571 is postulated to decrease hepatic 
TG sy nthesis and hepatic lipid burden in NAFLD and NASH.
2.1.Study Rationale 
The purpose of the study  is to evaluate the PK interactions between PF -06882961 and 
PF-06865571 in health y adult participants (Part A) and overweight adults or adults with 
obesity who are otherwise healthy (Part B) . 
2.2.Background 
2.2.1. Non-Alcoholic Steato hepatitis
NASH is a clinical and histological subset of NAFLD (defined as presence of ≥5% hepatic 
steatosis) that is associated with increased all -cause mortality , cirrhosis and end- stage liver 
disease, increased cardiovascular mortalit y, and increased incidence of both liver related and 
nonliver related cancers .14Prevalence of NAFLD is estimated in North America to range 
from 27% to 34%, while prevalence of NASH in the general US population is estimated at 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 25approximately  3-5%.15The 5 -year (67%) and 10- year (38%) survival rates for patients with 
NASH are significantly  different than for those with NAFLD.16The pooled liver -specific 
and overall mortality incidence rate estimates among those with NAFLD were calculated at 
0.[ADDRESS_1063457] the population with 
NASH, the incidence rate estimates were 11.8 (liver-specific) and 25.6 (overall) mortality.17
During a follow -up of mean 20 y ears (range 0 –40) equivalent to 139,163 person -years, 
12%
of NAFLD patients and 2.2% of controls developed severe liver disease (p=0.001) .[ADDRESS_1063458] s, and fibrosis .14As a consequence, a single 
drug is unlikel y to address all of the pathoph ysiologic components of NASH.  Combining 
therapi[INVESTIGATOR_774315] b iological targets and provide complementary  benefits on the 
disease pathoph ysiology  could provide greater efficacy  and/or better tolerability  to the 
patient and/or benefit for a larger fraction of the disease population than each individual 
monotherap y.  
2.2.2.
Nonclinical Pharmacokinetics
[IP_ADDRESS]. Nonclinical Pharmacokinetics and Metabolism of PF-06882961
Metabolism studies showed low turnover of PF- 06882961 with some oxidative and
glucuronide metabolites. All metabolites detected in human hepatocy tes were also observed
in hepatocy tes from nonclinical species. PF-06882961 is expected to be cleared via hepatic
uptake b y OATP, followed by [CONTACT_774329] y mediated b y CYP3A4/5, 
followed b y CYP2C8 andCYP2C19. Non-CYP enzy mes also contributed to the metabolis m 
of PF -06882961.
PF-06882961 is a BCRP substrate. In addition, b ased on in vitro data, PF -06882961 has the 
potential to inhibit intestinal BCRP with an IC50of 0.8 μM. Based on in vitro data, 
PF-06882961 demonstrate dtime-dependent inhibit ion ofCYP3A4/ 5.The rate of 
inactivation was not saturated within the concentration ranges tested (5 -150 μM), and 
therefore, the Kiand kinactcould not be calculated.
In vitro data also suggest a risk of PF
-06882961 interaction with drugs for which CYP2C8
and UGT1A1 mediated metabolism constitutes the primary  mechanism of clearance. At the 
dose of 200 mg BID, there is also a possibility  of weak inhibition of hepatic OATP1B3, 
OATP2B1, OCT1 and uptake transporter MDR1. Static modeling of in vitro data also 
indicate th atPF-06882961 has a low potential to cause DDIs as a result of induction of 
CYP3A4, or inhibition of other CYP enzy mes (1A2, 2B6, 2C9, 2C19 or 2D6), other UGT 
enzy mes (1A4, 1A6, 1A9, 2B7, 2B15), and uptake transporters OATP1B1, OCT2, MATE1, 
MATE2K, OAT1 a nd OAT3.
Refer to the IB for more details on the nonclinical PK and metabolism of PF -06882961.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Nonclinical Pharmacokinetics and Metabolism of PF-06865571
In pi[INVESTIGATOR_774316] 16- weeks in rats and monkey s, systemic exposure of 
PF-06865571 incr eased with increasing dose, although in a less than dose proportional 
manner.  In addition, PF -06865571 preferentiall y distributes into plasma versus red blood 
cells in vitro across the toxicology  species and humans.  I n vitro screening suggests that 
PF-06865571 is a substrate for MDR1 (also known as P-gp) and mBcrp efflux transporters.  
The major primary  metabolic pathway  identified from preliminary  in vitro and in vivo 
metabolite profiling in human is O -deeth ylation with subsequent sulfation and 
glucuroni dation , with 
no evidence of human -unique metabolites .  Reaction phenoty pi[INVESTIGATOR_774317] -06865571 metabolism was >96% with 
CYP3A being the predominant isoform.  Modeling suggests a moderate risk of clinical DDI 
with PF -[ADDRESS_1063459] 
planned clinical dose of 600 mg/day (300 mgBID).  PF -06865571 mediated DDIs associated 
with inhibition of CYP and UGT enzy mes are not expected, with the exception of CYP2C9, 
intestinal CYP3A4/5, UGT1A1, UGT1A9, and UGT2B15. In human hepatocy tes, 
PF-06865571 induces CYP2B6 and CYP3A4 (enzy matic and mRNA) but not CYP1A2. I n 
vitro evaluations indicated that PF -06865571 has a low potential to inhibit OAT1, OAT3, 
MATE2K, OATP1B1, and OATP1B3 transporters at clinically  relevant concentrations; 
however, PF -[ADDRESS_1063460] the potential to inhibit P -gp, BCRP, OCT1, OCT2, and 
MATE1.  
Refer to the IB for more details on the nonclinical PK and metabolism of PF -06865571.
2.2.3. Nonclinical Toxicology
[IP_ADDRESS]. Summary of Toxicology Studies with PF -06882961
PF-06882961 was administered to Wistar -Han rats and cy nomolgus monkey s in oral studies 
up to 6 months in duration. In addition, PF -06882961 was evaluated in genetic toxicity  
studies, dose -range -finding and definitive EFD studies in rats and rabbits, fertilit y and earl y 
embry onic study  in rats, and in vitro and in vivo phototoxicity  studies. PF-06882961 was not 
genotoxic or phototoxic. 
Based on the nonclinical toxicity studies conducted, effects were observed in the 
cardiovascular and gastrointestinal sy stems, liver, thy roid, and Harderian gland. The 
NOAELs in the 6- month toxicity  study in rats and 14 -week toxicity  study  in monkey s with a 
4-week lead -in(ie, the longest duration nonclinical studies supporting this clinical trial )were 
associated with s ystemic exposures (based on AUC 24) which are approximately 23x (for rat) 
and 1.2x (for monkey ) higher than the clinical exposures anticipated at the highest planned 
dose of 200 mg BID in C3421038.  The NOAEL in the 14 -week plus 4- week lead -in monkey  
toxicity  study  was based on decreases in food consumption and body  weight at a higher dose, 
which are considered monitorable and reversible. Please refer to Section 5.3.3 of the IBfor 
details.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Summary of Toxicology Studies with PF -06865571
InGLP-compliant studies, PF-06865571 was administered to rats in toxicity  studies up to 
6months in duration. I n the pi[INVESTIGATOR_758072] 6 -month toxicity  study  with 1- month 
(4-week) recovery , there were no adverse effects and no unique findings that were not 
evident in previous toxicity  studies. All test article- related ef fects were reversed at the end of 
the recovery  phase. TheNOAEL was 1000 (500 BID) mg/kg/day , the highest dose tested, 
based on the absence of any  adverse effects.
PF-06865571 was administered to cy nomolgus monkey s in GLP- compliant pi[INVESTIGATOR_774318] 9- months in duration. In the pi[INVESTIGATOR_22735] 9 -month chronic toxicity  study  with a 
1-month recovery , PF-06865571 was tolerated at all doses with no adverse or nonadverse 
findings. Therefore, 1000 (500 BID) mg/kg/day , the highest dose tested, was the NOAE L.
Additional details of nonclinical studies are provided in PF- 06865571 IB Section 5.3, and an 
overview of the toxicity  testing program is included in Table 5.3 -1 of the PF -06865571 IB.
[IP_ADDRESS]. Summary of Toxicology Study for Co-administration of PF -06882961 and
PF-06865571
In the completed 2 -week oral gavage toxicity  study  of the co -administration of PF -
06882961 
and PF-06865571 in Wistar Han r ats, PF -06882961 was administered once daily  at 
75mg/kg/day , and PF
-06865571 was coadministered twice dail yat 1000 (500 BID) 
mg/kg/day  by [CONTACT_27176] [ADDRESS_1063461] article -related effects were limited to higher liver weights in both sexes, 
minimal centrilobular hepatocellular h ypertroph y in a female, lo wer T3, T4, and cholesterol 
in both sexes, lower trigly cerides in males, and lower glucose in females. This 
coadministration was considered the NOAEL and was associated with a C maxof 5210 ng/mL 
and 18,500 ng/mL and AUC 24of 19,300 ng•h/mL  and 69,000 ng•h/mL on Day 14 in males 
and females, respectivel y, for PF -06882961. The corresponding PF -06865571 C maxof 
14,000 ng/mL and 29,400 ng/mL and AUC 24of 185,000 ng•h/mL and 427,000 ng•h/mL was 
obtained on Day 14 in males and females, respectively .
2.2.4. Clinical Ove rview
[IP_ADDRESS]. Summary of Clinical Safety
[IP_ADDRESS].1. Clinical and Safety Experience with PF- [ADDRESS_1063462] been completed with PF -
06882961 in which 135 participants 
were dosed, and 110 participants were exposed to single or multiple doses of PF -06882961 
(Table 6 -1 in the PF -06882961 IB). In addition, ongoing studies include a 16 -week Phase 2 
dose ranging stud y in T2DM (C3421005), a multiple dose PK/PD study in Japanese 
participants with T2DM (C3421015), a single dose ADME and oral bioavailability  study  
(C3421009) ,and a single dose formulation comparison study  in health y participants 
(C3421010). Two studies, C3421001 andC3421003, were completed in healthy  participants
(total of 37 health yparticipants randomized), and 1 study ,C3421002, was completed in
participants with T2DM
(total of 98 T2DM participants randomized). Inthese studies, 
PF-[ADDRESS_1063463] bo.  In 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 28C3421003, 12 healthy  participants were randomized to receive single doses of different oral 
formulations of PF- 06882961.   In C3421002, 98 participants with T2DM were randomized to 
multiple ascending oral doses of PF- 06882961 or placebo for 28 day s.In this study
PF-06882961 doses ranging from 10  mg BID to 120 mg BID were studied.  A total of 
98 participants with T2DM on a background anti- diabetic regimen of metformin were 
randomized to receive PF- 06882961 or matching placebo in a 3:1 randomization ratio, and 
92participants completed the study .  Six participants discontinued from the study , of which 
2discontinuations were due to treatment -related TEAEs and 4 withdrew during the treatment 
or follow -up period for non -treatment related reasons. A total of 319TEAEs were reported, 
of which themajorit y of the AEs [294 (92%)] were mild in severity , 23 (7%) were moderate, 
and 2 (1%) were severe in intensity .  The most frequently  reported TEAEs were nausea 
(49.0%), d yspepsia (32.7%), vomiting (26.5%), diarrhea (24.5%), headache (23.5%), and
constipation (20.4%). One participant experienced a mild TEAE of hy
pogly cemia.   This AE 
was non fasting, mild in severit y and of limited duration.   There were no deaths and no 
treatment -related SAEs with repeated do
sing of PF -[ADDRESS_1063464] been reported to date, of which the majority  of 
the AEs (127/129) were mild in severity  and 2 were moderate. There was 1 mild TEAE of 
increased transminitis (also reported as an SAE), which occurred at the end of the dosing 
duration, after co -administration of PF -[ADDRESS_1063465] been nausea (26), constipati on (12), decreased 
GFR (12), headache (10), and vomiting (9). While there were isolated values for laboratory  
tests, vital signs and ECG intervals outside of the reference ranges, no clear adverse trends 
were apparent in these parameters.  Mild declines f rom baseline were noted in GFR, with 
most values remaining above 70 mL /min, and occurred in the setting of weight loss, which 
was expected with the mechanism of action. Most GFR levels returned to pre-dose levels by  
[CONTACT_6492] -
up.
[IP_ADDRESS].2.
Clinical and Safety Experie nce with PF -[ADDRESS_1063466] been completed ( Table 6 -1 in the PF -06865571 
IB). In addition, ongoing studies include a 6-week Phase 2a study evaluating PF -06865571 
in combination with an ACC inhibitor in participants wi th NASH (C3711005) , a 48-week 
Phase 2b dose ranging study  evaluating PF -06865571 alone and in combination with an ACC 
inhibitor in participants with NASH
(C2541013), and a single dose ADME study  in health y 
participants (C2541007) . Across th
e [ADDRESS_1063467] been randomized.   This includes 132 unique healthy  adult participants and 148 adults 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 29with NAFLD.   Overall, 38  unique participants (14%) have been exposed to a single, oral dose 
of PF -
06865571 onl y; and an ad ditional 167 participants (60%) have received repeated doses 
of PF -06865571. In the clinical program, following single oral doses of PF -06865571, across 
the 300-fold dose range evaluated (ie, 5 mg to 1500 mg), the all causalit y, TEAEs reported in 
≥4participants were headache (12%) and diarrhea (7%).   Upon repeated administration of 
PF-06865571, across the 20 -fold dose range evaluated (ie, 90 to 1800 mg/day ),TEAEs
reported in ≥7 participants across all arms evaluated were headache (11%), diarrhea (6% ), 
fatigue (5%), pruritus (4%), abdominal pain (3%), and nausea (3%).   Across [ADDRESS_1063468]-randomization. These include 2 deaths, both considered unrelated to s tudy drug 
(Table 6.2-4 in PF -06865571 IB).  In the clinical experience to date, MTD has not been 
identified and with administration of PF- [ADDRESS_1063469] been no identified 
adverse drug reactions.
[IP_ADDRESS]. Summary of Clinical Pharmacology and Biopharmac eutic Studies
[IP_ADDRESS].1. Clinical Pharmacokinetics of PF -06882961
The clinical PK of PF -06882961 in adult participants has been evaluated in 3 completed 
studies: C3421001, C3421002, and C3421003.  The results of these completed studies are 
summarized in the PF -[ADDRESS_1063470] dose.  Mean t ½values r anged from 4.3 to 6.1 hours.  
Plasma exposure, as assessed by  [CONTACT_2715] -normalized geometric mean AUC infand C maxvalues, 
appeared to increase in a dose proportional manner across the 3 mg to 300 mg doses.   
Variability  in PF -06882961 exposure based on geometric %CV ranged from 50% to 91% for 
Cmaxand 28% to 60% for AUC infacross the [ADDRESS_1063471] for the BID IR formulation treatments, with mean ratios based on 
dose-normalized AUC 24(Rac) values ranging from 1.203 to 2.009. Day 28 plasma exposure 
as measured b y geometric mean AUC 24values appeared to increase in an approximate dose 
proportional manner across all I R treatments. Mean t ½values on Day 28 across all 
treatments ranged between 4.681 to 8.090 hours, and no apparent trends were observed 
across various treatments, regimens, or doses administered. Interparticipant variability  for 
PF-06882961 exposure was based on geometric mean was 31% -87% for AUC 24and 
32%- 94% for C maxand on Day 28 across all treatments and cohorts. A population PK model 
based on data from C3421001 and C3421002 indicated that the exposure in T2DM 
participants (C3421002) was approximately  1.7-fold higher than that observed in healthy  
participants (C3421001) after accounting for differences in bod y weight between the 
participants in each study.

PF-[ADDRESS_1063472] with drugs metabolized by [CONTACT_097]3A, as observed via co-administration with the sensitive probe CYP3A substrate, midazolam. When co-administered with 120 mg BID PF-06882961, midazolam C
maxand AUC lastdecreased by [CONTACT_3450] 37% and 49%, 
respectively. When co-administered with 200 mg BID PF-06882961, midazolam C maxand 
AUC lastdecreased by [CONTACT_3450] 28% and 45%, respectively.
Additionally, preliminary draft data from this study indicate a potential interaction between 
PF-[ADDRESS_1063473]
increased approximately 4.5-fold and 2.9-fold, respectively.
[IP_ADDRESS].2. Clinical Pharmacokinetics of PF-[ADDRESS_1063474] dose. Steady-state plasma concentrations were achieved by [CONTACT_2006] 4, and the mean terminal t
½ranged from 3.3-6.9 hours. Given the short mean terminal t ½accumulation 
is likely to be negligible at a dosing frequency of Q12H/BID as minimal accumulation was observed upon repeated dosing at a frequency of Q8H. Dosing in the fasted state resulted in lower exposures (ie, AUC
inf39% lower and C max34% lower than when a [ADDRESS_1063475] meal). Across the range of repeated doses evaluated (90 mg/day to 1800 mg/day, administered Q8H), the plasma exposure increased in a dose proportional manner. Less than 2% of the PF-06865571 dose administered was excreted unchanged in the urine indicating that renal clearance is not a major clearance 
mechanism for PF-06865571. PF-06865571, dosed at 300 mg BID, was shown to increase 
metformin (500 mg single dose) exposure (ie, both AUC
infand C max) by [CONTACT_3450] 
2-fold. 
2.3. Benefit/Risk Assessment
PF-06882961 and PF-06865571 are not expected to provide any clinical benefit to
participants in this study. This study is designed primarily to generate safety, tolerability, and PK data for further clinical development.
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-06882961 and PF-06865571 may be found in the IB for PF-06882961 and separately for PF-06865571, which are the SRSDs for this study.CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 312.3.1. Risk Assessment
Potential Risk of Cli nical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention –PF-06882961 (GLP -1receptor agonist)
Thyroid C -cell tumors The potential risks are based on product labeling 
for injectable GLP -1receptor agonists 
(ie,liraglutide, dulaglutide, and exenatide) due to 
dose- dependent and treatment 
duration -dependent thyroid C -cell tumors in 
nonclinical studies in rats and mice at clinically 
relevant exposures. 
Thyroid C -cell tumors have not been observed 
with PF -06882961 i n clinical or nonclinical 
studies.Potential participants with a personal or family 
history of medullary thyroid carcinoma or 
multiple endocrine neoplasia syndrome type 2 
(MEN2) are excluded from the clinical 
development program.  Thyroid function tests ar e 
included in the clinical trial protocols to monitor 
participants’ thyroid function.  
Pancreatitis The potential risks are based on product labeling 
for injectable GLP -1receptor agonists 
(ie,liraglutide, exenatide and dulaglutide). 
Pancreatitis has not been observed in the 
PF-[ADDRESS_1063476] an increased risk of hypoglycemia 
(such as insulin or sulfonylureas), an increased 
risk for hypoglycemia was observed. Participants 
with obesity who do not have co -existing T2DM
would not be taking anti -diabetic agen ts and 
therefore w ould not be expected to have an 
increased risk for hypoglycemia. Only one AE of 
mild hypoglycemia has been reported in the 
clinical development program to date.Anti-diabetic medications are prohibited in this 
study, and blood glucose is monitored as a part of 
the lab assessments at every clinical visit in this 
study.  Participants are informed about the signs 
and symptoms of hypoglycemia, and are 
monitored for these symptoms during the study.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 32Impairm ent in renal function In rats, minima l renal tubular vacuolation was 
observed, but this finding was considered to be 
non-adverse. In the clinical trial program ,only 
one mild AE(Preferred Term : blood creatinine 
increased) has been observed.Per exclusion criteria, potential participants wit h 
significant renal impairment are not eligible for 
study entry. Renal function is monitored at 
frequent intervals by [CONTACT_774330], creatinine ,andeGFR.
Gastrointestinal adverse reactions The potential risks are based on product labeling
for injectable GLP -1receptor agonists 
(ie,liraglutide, exenatide and dulaglutide).
In addition, gastrointestinal AEs, the majority of 
which were mild in severity, have been observed 
in the clinical program with PF -06882961. In 
nonclinical studies with PF -06882961, 
gastrointestinal AEshave been observed in rats 
and monkeys.Participants are monitored during the clinical 
studies to prevent potential sequelae of any severe 
gastrointestinal reactions (eg,dehydration ).  
Concomitant medication for nausea is permitted 
in the study. Additionally, PF -[ADDRESS_1063477] been reported for marketed 
GLP -1receptor agonists ( eg, liraglutide), and 
increases in HRhave been observed w ith 
PF-[ADDRESS_1063478] been 
incidences of HR >[ADDRESS_1063479] development of acute gallbladder 
disease.
Study Intervention –PF-06865571 (DGAT2 inhibitor)
Food effect resulting in change in PF-06865571
exposurePF-06865571 exposures are lower in fasted state 
than in fed state .Study interventions will be taken with a meal .
Fetal skeletal variations as a result of transient 
developmental delayIn an embryo-fetal development toxicity study in 
rats, low er fetal body weight and skeletal 
anomalies observed at all doses with NOAEL for 
this developmental toxicity not identified .In an 
embryo-fetal development toxicity study in 
rabbits, no developmental tox icity observed .Communicated through Section 7 of the 
PF-06865571 IB (Jan -2020 ).
Enrollment of WOCBP restricted to those using 
effective contraception .
In males who are sexually active with a female 
partner of childbearing potential, use of barrier 
methods not required/mandated given safety 
margins ≥100-fold.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 34Other
Risk of COVID -19 infection for participants During the pandemic, healthy participant scould 
be infected with the SARS -COV -2 virus through 
study participation. This could lead to increased 
health risk for participant sand others in the study
and could lead to confounding AE with study 
intervention.COVID -19 specific assessments according t o 
SoA.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 352.3.2. Benefit Assessment
While PF -06882961 and PF- 06865571 are not expected to provide any  clinical benefit to 
otherwise healthy  adult participants with obesity  in this study , potential benefits for 
participants in this study  may  include receiving medical evaluations/assessments associated 
with clinical study  visits (eg, phy sical examinations, ECGs, clinical safet y laboratory  
assessments ), and contributing to the process of developi[INVESTIGATOR_007] a potential new therap y for 
NASH with liver fibrosis.
2.3.3. Overall Benefit /Risk Conclusion
In consideration of the available clinical and nonclinical data, and the measures taken to 
minimize risk to participants in this study , the overall benefit /risk profile supports clinical 
testing of the combination of PF- 06882961 and PF -06865571. 

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 363. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Part A
Primary: Primary: 
•To evaluate the effects of PF-06865571 on the 
single-dose pharmacokinetics of PF-06882961 in 
healthy adult participants.•PF-06882961 plasma pharmacokinetic parameters: 
Cmaxand AUC 24.
Secondary: Secondary: 
•To evaluate the safety and tolerability of 
PF-06882961 alone and in combination with PF-06886571 when administered to healthy adult participants.•Assessment of treatment-emergent adverse events, 
clinical laboratory abnormalities, vital signs, body weight, and ECG parameters during the entire study.
Tertiary/Exploratory: Tertiary/Exploratory: 
•To evaluate the effects of PF-06865571 on additional 
pharmacokinetic parameters of PF-06882961 in healthy adult participants.•Additional PF-06882961 plasma pharmacokinetic 
parameters: 
Tmax.
Part B
Primary: Primary: 
• To evaluate the effects of PF-06882961 on the 
single-dose pharmacokinetics of PF-06865571 in overweight adults or adults with obesity who are otherwise healthy.• PF-06865571 plasma pharmacokinetic parameters on 
Day 1 and Day 47: 
Cmax, AUC last, and AUC inf,as 
data permits.
• To evaluate the effects of PF-06865571 on the 
multiple-dose pharmacokinetics of PF-06882961 in overweight adults or adults with obesity who are otherwise healthy.• PF-06882961 plasma pharmacokinetic parameters on 
Day 46 and Day 61: 
Cmaxand AUC 12.
Secondary: Secondary: 
• To evaluate the safety and tolerability of 
PF-06882961 and PF-06865571 when administered separately and in combination in overweight adults or adults with obesity who are otherwise healthy.• Assessment of treatment-emergent adverse events, 
clinical laboratory abnormalities, vital signs, body weight, and ECG parameters during the entire study.
• Assessment of mental health as determined by 
C-SSRS and PHQ-9 in Part B of the study.
Tertiary/Exploratory: Tertiary/Exploratory: 
• To evaluate the effects of PF-06882961 on additional 
pharmacokinetic parameters of PF-06865571 in overweight adults or adults with obesity who are 
otherwise healthy.• Additional PF-06865571 plasma pharmacokinetic 
parameters on Day 1 and Day 47: 
Tmax, CL/F, Vz/F, 
and t½, as data permits.
• To evaluate the effects of PF-06865571 on additional 
pharmacokinetic parameters of PF-06882961 in 
overweight adults or adults with obesity who are
otherwise healthy.• Additional PF-06882961 plasma pharmacokinetic 
parameters on Day 46 and Day 61: T maxand CL/F.
• To evaluate the effects of PF-06882961 on the 
multiple-dose pharmacokinetics of PF-06865571 in overweight adults or adults with obesity who are 
otherwise healthy.• PF-06865571 plasma pharmacokinetic parameters on 
Day 61: 
Cmax, Tmax, and AUC 12.CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 37 To evaluate the effects of multiple doses of 
PF-06882961 on CYP3A induction in overweight 
adults or adults with obesity who are otherwise 
healthy . Morning pre -dose 4-β-hydroxycholesterol/cholesterol 
plasma ratio on Days 1, 19, 31 , and 47.
 To evaluate the effect of mu ltiple doses of 
PF-06882961 on coproporphyrins I in overweight 
adults or adults with obesity who are otherwise 
healthy . CP-I parameters on Days 30 and 46: AUC 12and C max.
4.STUDY DESIGN
4.1.Overall Design
This study  will be conducted in [ADDRESS_1063480] of 
PF-06865571 on the multiple -dose PK of PF-06882961 inoverweight adults or adults with 
obesity who are otherwise healthy . 
In Period 1, a single oral dose of PF -06865571 will be administered. Following titration of 
PF-06882961 to a maximal stead y-state dose to be determined as described in Section 4.3
(Period 2), the effect of steady -state administration of PF -06882961 on a single oral dose of 
PF-
06865571 will be assessed ( Period 3). Following Period 3, multiple doses of 
PF-06865571 will be administered with a maximally  tolerated dose of PF - 06882961 to be 
determined as described in Section 4.3 (Period 4) to assess the effect of steady -state doses of 
PF-[ADDRESS_1063481], the preliminary  data 
from the C3421007 DDI study  indicate that PF -06882961 co-administration decreased the 
exposure of midazolam, a 
probe 3A4 substrate. To investigate the mechanism of this 
interaction, plasma 4- -hydroxycholesterol/cholesterol, used as an endogenous probe for 
CYP3A induction, will be collected and anal yzed in this study .
At the PF-06882961 200 mg BID dose , there is a possibility  of weak inhibition of the hepatic 
uptake transporters OATP1B3 and OATP2B1.  CP -Ihas been reported to be used as an 
endogenous probe for OATP1B activi ties.  In the clinical DDI study  of rosuvastatin and 
rifampi[INVESTIGATOR_2513], CP -I exposure (AUC 24) was increased by  4.0-fold with co -administration of 
rifampi[INVESTIGATOR_2513], a potent OATP1B1 inhibitor, c ompared to the group of rosuvastatin alone.[ADDRESS_1063482] of PF -06882961 on 
OATP1B at higher doses (ie, 120 and 200 mg BID).   This data could help understand the 
contribution of OATP1B inhibition to the rosuvastatin exposure increase observed in the 
C3421007 study  where rosuvastatin was co -
administered with PF- 06882961.   In the study  
mentioned above, it was also suggested that CP -I plasma concentration at baseline were 
constant and independent of time, but changed rapi[INVESTIGATOR_774319]-administration with 
rifampi[INVESTIGATOR_774320] 24 hours.28  Therefore, three blood samples 
will be taken 
at different timepoints prior toPF-06882961 treatment in Part B to determine 
baseline CP-I concentrations followed by  [CONTACT_50637]-I concentration time profiles over 12hours for 
both PF-06882961 120 mg and 200 mg BID at stead y-state, respectivel y.
Participants with a higher BMI range from 25 kg/m2to 40kg/m2who are overweight or 
obese but otherwise healthy  will be enrolled in Part B to target a similar BMI  range as 
patients with NASH . Adult participants with NASH often have co -existing obesit y, and 
PF-06882961 will likely  be co-administered with PF-06865571 in a future clinical efficacy  
study . 
The elimination half-lives ofPF-06882961 and PF- 06865571 are approximately  ≤8hours
and ≤7hours , respectively , following single and multiple dosing . Therefore ,plasma 
sampling will be collected for [ADDRESS_1063483] been shown to increase with marketed GLP-1receptor agonists.
20-23In addition, TSH, free T4, lipi[INVESTIGATOR_805], coagulation profile, and TBA will 
also be assessed based on non-adverse findings in the nonclinical studies with PF-06882961. Furthermore, PF-06865571 is a dose-dependent inhibitor of the transporters OCT2/MATE in the kidney and, as expected, this has been observed to cause increases in serum creatinine in previous clinical studies with PF-06865571 without a change in renal function, as assessed via measurements of Cystatin-C.  Therefore, Cystatin-C (and eGFR using CKD-EPI-Cystatin-C) will be measured in Part B to accurately monitor renal function starting at baseline and throughout the study.  Assessment of suicidal ideation and behavior will be conducted using C-SSRS,
24and PHQ-925will also be performed based on the 
potential risk related to the product labeling for the injectable GLP-[ADDRESS_1063484] liraglutide
23in patients with BMI ≥30 kg/m2.
While GLP-1 receptor agonists typi[INVESTIGATOR_774321]-administered with anti-diabetic agents th at can cause hypoglycemia (such as insulin or 
sulfonylureas), blood glucose concentrations will be monitored throughout the study via 
laboratory assessments, and monitoring of symptomatic hypoglycemic will be performed. In 
addition, all participants will be instructed regarding the symptoms associated with, and management of, hypoglycemia, which will permit the monitoring of symptomatic HAEs.
Dosing of both PF-[ADDRESS_1063485] been noted (refer to Section 2.3.1 ). The use of a highly 
effective method of contraception is required by [CONTACT_774331]. Refer to Section 5.3.4 , Section 6.5 , and Appendix 4 for additional 
details. 
The potential risk of exposure to PF-06882961 and/or PF-06865571 in a sexual partner of a 
male participant in this study via ejaculate is low, and therefore no contraception (condom) use in male participants is warranted. The calculated safety margin is ≥100-fold between the 
estimated partner exposure due to seminal transfer and the NOAEL for serious manifestations of developmental toxicity in nonclinical studies.  The safety margin of 100-fold is based on applying a 10-fold safety factor for interspecies extrapolation and a 10-fold safety factor for susceptible populations.
[ADDRESS_1063486] exposure increases of PF-06882961 are anticipated in this study, a 20 mg dose of PF-06882961 is anticipated to be safe and generally well tolerated in healthy adult participants even if a potential PK drug-drug interaction increases the exposure of PF-06882961.
[IP_ADDRESS]. PF-[ADDRESS_1063487] planned steady-state dose in the Phase 2 obesity POC study is 200 mg BID 
(C3421019). Similarly, [ADDRESS_1063488] planned steady-state dose in a drug interaction study (C3421007) investigating the effect of PF-06882961 on the PK of midazolam (3A4 substrate) and rosuvastatin (BCRP substrate). Based on a population PK analysis of Phase 1 data including both T2DM and non-T2DM participants, the exposure in T2DM participants are projected to be 1.7-fold higher than non-T2DM. Based on this 
analysis, the exposure in participants with obesity in these studies are expected to be 
comparable to the exposure of 120 mg BID in T2DM, which was generally well tolerated in the multiple ascending dose study C3421002. However, no clinical data are available (at the time of finalization of this protocol) evaluating doses >120 mg BID in any participant population. 
Preliminary safety and tolerability data from C3421007 will be reviewed prior to final dose 
and titration scheme selection for this study. If 200 mg BID is well tolerated in C3421007, then a steady-state dose of 200 mg BID will be used in this study. If 200 mg BID is not well tolerated in C3421007, then a lower steady-state dose will be selected for this study. CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 42Accordingl y, the maximal practical and well tolerated dose of PF -06882961 is envisioned for 
use in this study .This is consistent with expectation that the PF -06882961 dose needed for 
treatment of NASH is similar to that required for maximal efficacy  in obesi ty.
The titration to PF -06882961 200 mg BID is planned over approximately  44 day sbut may  
also be revised b ased on C3421007 study  results. Part B doses of PF- 06882961 may be 
reduced if PF -06865571 increases PF -06882961 AUC 24by >50% in Part A.
The titration scheme is outlined in Section 6.1.[ADDRESS_1063489] completed the study  if he/she has completed all phases of 
the study ,including the follow -up contact, approximately  [ADDRESS_1063490] visit (follow -up contac t) of the last 
participant in the study .
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollmen t criteria ,also 
known as protocol waivers or exemptions, is not permitted .

PF-[ADDRESS_1063491] y:
Age and Sex :
1.Male and female p articipants must be 18 to 65 years of age, inclusive, at the time of 
signing the ICD .
Women can be of child -bearing potential, however, cannot be pregnant, 
breastfeeding, or planning to become pregnant while participating in the study .
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Male and female participants who are overtl y healthy (other than being overweight or 
obese in 
Part B onl y) as determined b y medical evaluation including medical history, 
physical examination, andlaboratory  tests.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, a nd other study  procedures.
Weight:
4.BMI and total bod y weight:
Part A: BMI of 17.5 to 30.5kg/m2; and a total body  weight >50 kg (110 lb);
Part B: 
BMI ≥25 kg/m2and not more than 40kg/m2at Screening ; stable body  
weight, defined as <5 kg change (per participant report) for 90 day s before 
Screening .
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurologic al, or 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 44allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing) .
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stecto my,
bariatric surgery , active inflammatory  bowel disease ,or an intestinal resection ).
3.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -
19 pandemic (eg, contact [CONTACT_216478], residence or 
travel to an area with high incidence) that may  increase the risk of study  participation 
or, in the investigator’s judgment , make the participant inappropriate for thestudy .
4.Known intolerance or h ypersensitivity  to GLP -1receptor agonists.
5.Known intolerance or h ypersensitivity  to DGAT2 inhibitors.
6.Diagnosis of t ype 1 or t ype 2 diabetes mellitus or secondary forms of diabetes at 
screening. Note: women with prior diagnoses of gestational diabetes during 
pregnancy  only are eligible if they  meet the other eligibility  criteria.
7.History  of m yocardial infarction, unstable angina, arterial revascularization, stroke, 
[LOCATION_001] Heart Association Functional Class II -IV heart failure, or transient 
ischemic attack within 6 months of Screening.
8.Any malignancy  not considered cured (except basal cell carcinoma and squamous cell 
carcinoma of the skin); a study  participant is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years (from Screening).
9.Personal or famil y history of medullary  thyroid carcinoma or multiple endocrine 
neoplasia s yndrome t ype 2, or study participants with suspected medullary  thyroid 
carcinoma per the investigator’s judgment .
10.Acute pancreatitis or history  of chronic pancreatitis.
11.Symptomatic gallbladder disease.
12.Medical history  or characteristics suggestive of genetic or s yndromic obesity  or 
obesity  induced b y other endocrinological disorders (eg, Cushing S yndrome).
13.History  of major depressive disorder or history of other severe ps ychiatric disorders 
(eg, schizophrenia or bipolar disorder) within the last 2 y ears from screening.
14.Known medical history  of active liver disease (other than non
-alcoholic hepatic 
steatosis), includi ng chronic active hepatitis B or C, primary  biliary  cirrhosis, 
alcoholic liver disease, primary  sclerosing cholangitis, autoimmune hepatitis, overlap 
syndrome, or prior known drug -induced liver injury .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 4515.History  of HIV infection.
16.Any lifetime history  of a su icide attempt.
Prior/Concomitant Therapy:
17.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention .  (Refer to Section 6.5for additional details).
18.See Section 6.5 for prohibited prior/concomi tant medications.
Prior/Concurrent Clinical Study Experience:
19.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_1063492] dose of study  intervention
used in this study  (whichever is longer).   An emergency  use authorized or approved 
COVID -19 vaccine is considered a concomitant medication.
20.
Known prior participation in a clinical trial with PF- 06882961 or PF -06865571.
Diagnostic Assessments:
21.Part B onl y: A Patient Health Questionnaire (PHQ -9) score ≥ 15 obtained at Screening 
or Day  -1.
22.Part B onl y: Response of “y es” to question [ADDRESS_1063493].
24.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_1063494].  If BP is ≥140 mmHg (sy stolic) or ≥90 mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the partic ipant’s eligibility .
25.Screening [ADDRESS_1063495] participant safety or interpretation of study results (eg, baseline QTc interval 
>[ADDRESS_1063496]- degree AVblock, or serious brady arrhy thmias or tachy arrhy thmias).  If the 
baseline uncorrected QT interval is >450 msec, this interval should be rate- corrected 
using the Fridericia method and the resulting QTcF should be used for decision 
making and reporting.   If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG 
should be repeated 2 more times and the average of the 3 QTc or QRS values should 
be used to determine the participant’s eligibility . Computer -interpreted ECGs should 

PF-[ADDRESS_1063497], if deemed necessary :
HbA1c ≥6.5%.
AST or ALT >ULN.
Total bilirubin level >ULN; participants with a history  of Gilbert's s yndrome may  
have direct bilirubin measured and areeligible for this study  provided the direct 
bilirubin level is ≤ULN.
TSH > ULN or < LLN.
Serum calcitonin > ULN.
Amy lase or lipase > ULN.
Fasting blood gluco se ≥126 mg/dL.
Fasting trigl ycerides >200 mg/dL.
INR > ULN.
PLT <LLN.
eGFR <80 mL/min/1.73 m2as calculated b y the CKD -EPI [INVESTIGATOR_10908].
Positive testing for HIV, HepBsAg, or HCVAb. Study  participants positive for 
HCVAb are to be excluded unless known to have been treated with a known 
curative therap y and negative for HCV RNA. Hepatitis B vaccination is allowed.
Other Exclusions (at Screening unless indicated ):
28.Participation in a formal weight reduction program (eg, Weight Watchers) within 
90days prior to 
Screening.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 4729.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening.  Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours .  As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine).
30. Current use of tobacco or nicotine containing products in excess of the equivalent of 
5cigarettes per da y.
31.Known or suspected illicit drug use.
32.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within 60 days prior to dos e randomization (Day  -1).
33.History  of sensitivity  to heparin or heparin -induced thrombocy topenia if Hep -
lock is 
used for IV blood draw .
34.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol
.
35.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 8hours prior 
to any  safety laboratory  evaluations and the morning predose PK evaluations.
Water may  be consumed as desired (ad libitum).
Participants should begin consumption of a standard breakfast (morning) and dinner 
(evening )approximately  [ADDRESS_1063498] and dinner will be 
consumed over approximately  a 20 minute period, with the study  intervention 
administered within approximately  10 minutes after completion of the meal. 
Participants will be encouraged to complete the entire meal. Study  intervention will 
be administered as outlined in Section 6.1.1 . 
Noncaffeinated drinks (except red wine, grapefruit or grapefruit -related citrus fruit 
juices; see below) may  be consumed with meals and the evening snack. Caffeine 
containing drinks may  be consumed during the study  but not within 1 hour prior to 
measuring vital signs and ECGs (see Section 5.3.2 ) .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 48Lunch will be provided approximately  4hours after morning dosing.
On Overall Study  Day  46, Day  47, and Day  61in Part B , dinner will be provided 
approximately  12 hours after morning dosing. On all other study  daysin both Part A 
and Part B , dinner will be provided approximately  10hours after morning dosing .
An evening snack may  be permitted.
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1063499] 
dose of study  intervention until collection of the final PK blood sample. 
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein.  The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Tobacco or nicotine use may  be allowed according to CRU practices but not in excess 
of the equivalent of 5 cigarettes per day as outlined in Section 5.2.
Tobacco or nicotine use will not be permitted during frequent sampling procedures 
and will not be permitted within 2 hours prior to any  vital sign or ECG assessments. 
Tobacco or nicotine use will also not be permitted 2 hours before and 2 hours 
following an y dose of study  intervention. 
Caffeine containing products will be permitted during the stud y with the following 
restrictions: caffeine containing products may  not be consumed within 1 hour prior to 
measuri ng vital signs and ECGs.
Participants will abstain from alcohol for [ADDRESS_1063500] at the discretion 
of the investigator.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted .
In order to standardize the conditions on PK sampling day s, participant s will be 
required to refrain from ly ing down, eating, and drinking beverages other than water 
during the first [ADDRESS_1063501] -dose PK sample 
collections (except when required for BP, PR, and ECG measurements) . 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 495.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception).  In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known 
or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported to the clinical database.
A participant who qualified for this protocol but did not enroll within the 28 -day screening 
window due to unexpected delay s (eg, delay ed drug shipment), will not be required to 
rescreen if the laboratory results obtained prior to first dose administration meet eligibility  
criteria .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened. 
6.STUDY INTERVENTION
Study  intervention is defined as any  invest igational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol , study  intervention refers to PF -06882961 and
PF-
06865571. 
6.1.Study Intervention(s) Administered
PF-06882961 tablets ( 10 mg, 40 mg, and 100 mg )will be supplied by  [CONTACT_774332], as necessary , for unit dosing.
PF-06865571 t ablets (100 mg) will be supplied by  [CONTACT_774333] , as necessary , for unit dosing .

PF-[ADDRESS_1063502] a t approximately  0800 hours (plus or minus 2 hours).
In Part B, participants will receive PF -06882961 and PF -06865571 as applicable per SoA . 
Morning doses will be administered at approximately  0800 hours (plus or minus 2 hours). 
For BID dosing on O verall Study Day 46, Day  47, and Day  61, evening dosing of 
PF-06865571 and/or PF
-06882961 will occur approximately  12hours after morning dos ing. 
On all other study  days, evening dos ingof PF-06865571 and/or PF -06882961 will occur 
approximately  10hours after morning dos ing. Details on meals and dietary  requirements and 
activity  restrictions on dosing day s are given in Section 5.3.  
Investigator site personnel will administer PF -
06882961 and PF-06865571 during each 
period (as applicable per SoA) with ambient temperature water to a total volume of 
approximately  240 mL. Participants will swallow the study  intervention whole and will not 
manipulate or chew the study  intervention prior to swallowing.
Administration of study  intervention will occur as listed in the SoA and Table 4(Part A) and 
Table 5(Part B) .
Table 4. Part A Dosing
Study Treatment Drug and Dosage
Treatment A Day 1: PF -06882961 20 mg single dose
Treatment B Day 1: PF -06882961 20 mg single dose plus PF-06865571 300 mg single dose
Table 5. Part B Dosing
Study Period Days in Study Drug and Dosage
Period 1, Day 1 1 PF-06865571 300 mg single dose
Period 1, Day 2 2 No study intervention administered
Period 2, Days 1 -4 3-6 PF-06882961 10 mg BID
Period 2, Days 5 -8 7-10 PF-06882961 20 mg BID
Period 2, Days 9 -12 11-14 PF-06882961 40 mg BID
Period 2, Days 13 -16 15-18 PF-06882961 60 mg BID
Period 2, Days 17 -20 19-22 PF-06882961 80 mg BID
Period 2, Days 21 -24 23-26 PF-06882961 100 mg BID
Period 2, Days 25 -28 27-30 PF-06882961 120 mg BID
Period 2, Days 29-32 31-34 PF-06882961 140 mg BIDa
Period 2, Days 33-36 35-38 PF-06882961 160 mg BIDa
Period 2, Days 37-40 39-42 PF-06882961 180 mg BIDa
Period 2, Days 41-44 43-46 PF-06882961 200 mg BIDa
Period 3, Day 1 47 PF-06865571 300 mg single dose plus PF-06882961 200 mg BIDa
Period 3, Day 2 48 PF-06882961 200 mg BIDa
Period 4, Days 1 -13 49-61 PF-06865571 300 mg BID plus PF-06882961 200 mg BIDa

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 51Study Period Days in Study Drug and Dosage
Period 4, Day 14 62 No study intervention administered
a.Doses of PF -06882961 may be reduced based on PK results of Part A of this study and safety and 
tolerability results of Study C3421007.
6.2.Preparation/Handling/Storage/Accountability
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.   All study 
interventions must be stored in a secure, environmentally
 controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximu m temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.
Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken.  The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible.  Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention.  Specific details regarding the definition of an excursion 
and inf ormation the site should report for each excursion will be provided to the site 
in the IP Manual .
Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
Study  interventions should be stored in their original containers.
The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition r ecords) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
Further guidance and information for the final disposition of unused study  
interventions are pro vided in the I P manual .  All destruction must be adequately  
documented.  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulati ons, institutional policy , and any  special instructions 
provided b y [COMPANY_007].

PF-[ADDRESS_1063503] complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, pr eparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479].  Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol.  L ocal health authority  regulations or 
investigator site guidelines may  use alternative terms for these activities.
Tablets will be prepared at the CRU in the individual dosing containers b y 2operators, 1 of 
whom is an appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, phar macy  assistant/technician, or pharmacist).  
The tablets will be provided in unit dose containers and labeled in accordance with [COMPANY_007] 
regulations and the clinical site’s labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocat ion to Study I ntervention
This is an open -label study . The investigator’s knowledge of the treatment should not 
influence the decision to enroll a particular participant or affect the order in which 
participant s are enrolled.
The investigator will assign participant numbers to the participants as they  are screened for 
the study .  The first [ADDRESS_1063504] each participant’s unique 
number assign ed in chronological order as informed consent is obtained.  In addition, on 
Day [ADDRESS_1063505], 2 digit number (as provided to 
the si te by  [CONTACT_941] s ponsor at the start of the study ) to enable execution of the sponsor ’s standard 
processes for analy sis of all PK -related samples.
Participants will receive doses of PF -06882961 and PF -06865571 as described in Table 6
(PartA Sequence 1), Table 7(Part A Sequence 2), and Table 8(Part B) .
Table 6. Part A Sequence 1 –Dosing Re gimens for PF -06882961 and PF -06865571
Period DayAM/
PMDoseNumber of PF ‑06882961 
TabletsNumber of 
PF‑06865571 
TabletsTotal Number 
of Tablets
10 mg 40 mg 100 mg 100 mg
1 1 AM 20 mg PF ‑06882961 2 2
2 1 AM20 mg PF ‑06882961
and 
300 mg PF‑068655712 3 5

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 53Table 7. Part A Sequence 2 –Dosing Regimens for PF -06882961 and PF -06865571
Period DayAM/
PMDoseNumber of PF ‑06882961 
TabletsNumber of 
PF‑06865571 
TabletsTotal Number 
of Tablets
10 m g 40 m g 100 m g 100mg
1 1 AM20 mg PF ‑06882961
and 
300 mg PF ‑068655712 3 5
2 1 AM 20 mg PF ‑06882961 2 2
Table 8. Part B – Dosing Regimens for PF- 06882961 and PF -06865571
PeriodDay(s)
in 
StudyAM/
PMDoseNumber of PF ‑06882961 
TabletsNumber of 
PF‑06865571 
TabletsTotal 
Number 
of Tablets10 m g 40 m g 100 m g 100 m g
11 AM 300 mg PF ‑06865571 3 3
2 N/ANo study intervention 
administered0
23-6AM 10 mg PF ‑06882961 1 1
PM 10 mg PF ‑06882961 1 1
7-10AM 20 mg PF‑06882961 2 2
PM 20 mg PF ‑06882961 2 2
11-14AM 40 mg PF ‑06882961 1 1
PM 40 mg PF ‑06882961 1 1
15-18AM 60 mg PF ‑06882961 2 1 3
PM 60 mg PF ‑06882961 2 1 3
19-22AM 80 mg PF ‑06882961 2 2
PM 80 mg PF ‑06882961 2 2
23-26AM 100 mg PF ‑06882961 1 1
PM 100 mg PF ‑06882961 1 1
27-30AM 120 mg PF ‑06882961 2 1 3
PM 120 mg PF ‑06882961 2 1 3
31-34AM 140 mg PF ‑0688296a1 1 2
PM 140 mg PF ‑06882961a1 1 2
35-38AM 160 mg PF ‑06882961a2 1 1 4
PM 160 mg PF ‑0688296a2 1 1 4
39-42AM 180 mg PF ‑0688296a2 1 3
PM 180 mg PF ‑06882961a2 1 3
43-46AM 200 mg PF ‑06882961a2 2
PM 200 mg PF ‑06882961a2 2
347AM200 mg PF ‑06882961a
and
300 mg PF ‑068655712 3 5
PM 200 mg PF ‑06882961a2 2
48AM 200 mg PF ‑06882961a2 2
PM 200 mg PF ‑06882961a2 2
449-61AM200 mg PF ‑06882961a
and
300 mg PF ‑068655712 3 5
PM200 mg PF ‑06882961a
and
300 mg PF ‑068655712 3 5
62 N/ANo study intervention 
administered0

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 54PeriodDay(s)
in 
StudyAM/
PMDoseNumber of PF ‑06882961 
TabletsNumber of 
PF‑06865571 
TabletsTotal 
Number 
of Tablets10 m g 40 m g 100 m g 100 m g
a. Doses of PF -06882961 may be reduced based on PK results of Part A of this study and safety and tolerability results 
of Study C3421007.
6.4. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second qualified member of the study  site staff.
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee , under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention.  Study  site personnel will exam
ine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Concomitant Therapy
Study  participants will abstain from all concomitant treatments, except for the treatment of 
adverse events, as described in Section 5.2of this protocol.
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . 
Limited use of nonprescription medications that are not believed to affect participant safety  
or the overall results of the study  may  be permitted on a case -by-case basis following
approval b y the sponsor .  Acetaminophen/paracetamol may  be used at doses of ≤ 1g/day .
Anti- emetics (eg, prochlorperazine, promethazine, ondansetron) may  be administered at the 
investigator’s discretion with notification to the sponsor and entry  in the CRF (see 
Section [IP_ADDRESS]).
Sites are encouraged to contact [CONTACT_486830] a 
medication is permitted or prohibited.
Hormonal contraceptives are not allowed to be used in participants who are WOCBP (see 
Appendix 4).
Females using hormonal contraceptives or taking hormone replacement therap y ma
y be 
eligible to participate in this study  if they  are willing to discontinue therapy at least [ADDRESS_1063506] dose of study  treatment and remain off hormonal therap y for the duration of 
the study .  Depo- Provera®must be discontinued at least [ADDRESS_1063507] dose of study  intervention
will be documented as concomitant treatments.
6.5.1. Rescue Medic ine
There is no rescue therapy  to reverse the AEs observed with PF-06882961 or PF -06865571; 
standard medical supportive care must be provided to manage the AEs , including 
administration of carbohydrates to treat HAEs (see Section 8.2.8 ).
[IP_ADDRESS]. Management of Nausea and Vomiting
Nausea and vomiting have been reported with administration of GL P-1receptor agonists and 
also with administration of PF -06882961. Study  participants complaining of nausea may  be 
managed conservativel y with bed rest and/or fluid management at the discretion of the 
investigator. If the nausea and vomiting are not amenable to conservative management, 
anti-emetics (eg, prochlorperazine, promethazine, ondansetron) may  be administered at the 
investigator’s discretion with notification to the sponsor and entry  in the CRF.
6.6. Dose Modification
If participants are not able to tolerate titration to higher doses of PF -06882961 
(eg, >120 mgBID) in Part B , titration to the next dose level may  be delay ed temporaril y or 
titration to maximum tolerated dose may  be permitted with Sponsor approval only .
Part B d oses of PF -06882961 may be reduced in this study based on safet y and tolerability 
results of Study C3421007. The duration of each titration s tep 
may also be revised. PartB 
doses of PF -06882961 may be reduced if PF -06865571 increases PF -06882961 AUC 24by 
>50% in Part A. 
6.7.Stoppi[INVESTIGATOR_1869]
6.7.1. Participant Death
In the event that there is death of a parti cipant, trial conduct will be paused and the death 
assessed for causality  and relatedness b y the medical monitor.
Sponsor will notify the FDA in the event of a participant death in accordance with IND 
safet y reporting requirements under 21 CFR 312.32(a) an d 312.32(c)(1).

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 566.7.2. Individual Participant Development of Adverse Events (Part B only)
If a participant experiences a severe AE, and the AE is assessed to be related to GL P-[ADDRESS_1063508] pharmacology  and/or anticipated to develop toleration (eg, nausea, v omiting, 
anorexia), dosing may  continue with protocol permitted mitigations as needed 
(eg,antiemetics; see Section 6.5Concomitant Therap y).  If the anticipated improvement in 
tolerability  is not observed, the study  intervention dosing will be discontinued for that 
participant. 
If the AE is not known to be re lated to GL P-[ADDRESS_1063509] pharmacology , not anticipated 
to develop toleration, or has not y et been assessed as unrelated to study  intervention, dosing 
of study  intervention should be discontinued for the affected participant and the AE should 
be asse ssed for causality  and relatedness.
6.7.3. Cohort Level Assessment of Adverse Events (Part B, Period 4 only)
During Part B (Period 4 )if: 
a.Three participants develop the “same” moderate AE; 
or
b. T wo participants develop the “same” severe AE;
and
c.If the AE is not known to be related to GL P-[ADDRESS_1063510] pharmacology .
The trial should be paused and AE should be assessed for causality and relatedness.  If the 
medical team/medical monitor and investigator together deem causality  to be unrelated to 
study  intervent ion use, trial conduct may  be continued.  
If (a) or (b) occur, but not (c), ie, an AE is assessed to be related to GLP -[ADDRESS_1063511] 
pharmacology  and/or anticipated to develop toleration (eg, nausea, vomiting, anorexia), 
dosing may  continue with prot ocol permitted mitigations as needed (eg, antiemetics; see 
Section 6.5 Concomitant Therap y).  If the anticipated improvement in tolerability  is not 
observed, the stud y intervention dosing will be discontinued for that participant.
6.8.Intervention A fter the End of the Study
No intervention will be provided to study participants at the end of the study .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 577.DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) .Reasons for definitive disco ntinuation of study  
intervention include the following :
Criteria for a potential Hy ’s law case are met (see Appendix 6 ).
Intent to become pregnant or pregnancy  confirmed by  [CONTACT_11084] -hCG testing.
Safety  or tolerabilit y concern arises, in particular if not responsive to s ymptomatic 
management, dosing with study  intervention may  be stopped in an individual 
participant at investigator discretion.
Based on mental health assessment as outlined in Section 8.2.5, should be 
discontinued from dosing at investigator discretion.
If the criteria for permanent discontinuation are met, the site should notify  the sp onsor 
Medical Monitor or sponsor Clinician .
Note that discontinuation of study  intervention does not represent withdrawal from the study .  
If study  intervention is definitively  discontinued, the participant will remain in the study  to 
be evaluated through 
the follow -up contact . See the SoA for data to be collected at the time 
of discontinuation of study  intervention and follow -up for any  further evaluations that need 
to be completed.
In the event of discontinuation of study  intervent ion, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional inf ormation.
ECG Changes
See Appendix 7 for additional guidance of ECG findings of potential clinical concern.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request .  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 58Study  terminated by  [CONTACT_3211] ;
Safety  or behavioral reasons at the discretion of the investigator, including reasons 
related to mental health assessments as described in Section 8.2.5 .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and fo r any further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .  Participants should be questioned regarding 
their reason for withdrawal.   
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested
,and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258].  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is only  from f urther receipt of study  intervention or also from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital status (whether the participant is alive or dead) is being measured, publicly  
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is u nable to be contact[INVESTIGATOR_530] b y the study  site.

PF-[ADDRESS_1063512] be taken if a participant fails to return to the clinic for or attend a 
required stud y visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator o r designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_774334] b e documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investiga tor site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population crit eria for the study .  If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration m eet eligibility  criteria.

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 60A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory results obtained prior to the first dose administration meet eligibility criteria for this study. In addition, other clinical assessments or specimen collectionsmay be used without repeat collection, as appropriate.
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform the test.  In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant.  When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that he or she has taken to ensure that required processes are adhered to as soon as possible.  The study team must be informed of these incidents in a timely manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_774335].
The total blood sampling volume for individual participants in this study is approximately 
140 mL for Part A and approximately 525 mL for Part B.  The actual collection times of blood sampling may change.  Additional blood samples may be taken for safety assessments at times specified by [CONTACT_4618], provided the total volume taken during the study does not exceed 550 mL during any period of 60 consecutive days.
To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations and Concomitant Therapy sections of the protocol.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
8.2.1. Physical Examinations
A complete physical examination will include, at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 61A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
A complete ph ysical exam will be done at time points specified in the SoA, otherwise, brief 
exam will be conducted if findings during previous exam or new/open AEs, if app ropriate, at 
investigator discretion.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. Height will be 
measured at screening only . Weight will be recorded using a calibrated scale (with the same 
scale used if possible for the duration of the stud y) reporting weight in either pounds (lb) or 
kilograms (kg), and acc uracy  to the nearest 0.2 lb (or 0.1 kg); ie, the device must be able to 
distinguish a difference between 150.4 lb (68.4 kg) versus 150.2 lb (68.3 kg). The scale must 
be placed on a stable, flat surface.
Weight measurement should be taken under the followi ng conditions:
In the morning in a fasting state.
After void of urine.
After removal of shoes, bulky  layers of clothing and jackets so that only  light clothing 
remains.
Remove the contents of their pockets.
While remaining still during the measurement.
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235] ’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately [ADDRESS_1063513].  The same arm 
(preferabl y the dominant arm) will be used throughout the study. Participant s should be 
instructed not to speak during measurements. When triplicate measurements are obtained, 
they should be collected approximately  2 minutes apart.
At screening, the participant’s arm circumference should be measured (eg, using a flexible 
anthropometric tape) at the midpoint of the length of the upper arm and the appropriate cuff 
selected and used throughout the study .The same properl y sized and calibrated BP cuff will 
be used to measure BP each time.  The use of an automated device for measuring BP and 
pulse rate is acceptable; however, when done manually , pulse rate will be measured in the 
brachial/radial artery  for at least [ADDRESS_1063514] 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex .Alternative lead placement methodology using torso leads (eg ,Mason- Likar) is not 
recommended given the potential risk of discrepancies with ECGs acquired using standard 
limb lead placement.  All scheduled ECGs should be performed after the participant has 
rested quietly for at least 10 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc interval is increased b y ≥60msecfrom the ba seline and is >450 msec; or b) an 
absolute QTc value is ≥[ADDRESS_1063515] hourly  until QTc 
values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTc interval remains ≥60msecfrom the baseline andis >450 msec; or b) an 
absolute QTc value is ≥500 msecfor any  scheduled ECG for greater than 4 hours (or sooner, 
at the discretion of the investigator); or c) QTc intervals get progressivel y longer, the 
participant should undergo continuous ECG monitoring. A cardiologist should be consulted 
if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be ap propriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.

PF-[ADDRESS_1063516] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values consider ed clinically  significantl y abnormal during 
participation in the study  or within 28-[ADDRESS_1063517] dose of stud y intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinicall y 
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.5. Suicidal Ideation and Behavior Risk Monitoring
[IP_ADDRESS]. Columbia Suicide Severity Rating Scale ( Part B only)
The C -SSRS is an interview based rating scale to sy stematically  assess suicidal ideation and 
suicidal behavior .24The “baseline/screening” version of the C -SSRS will be administered at 
Screening and Day  -1 in study . Participants who respond “y es” to Question 4 or 5 (indicating 
suicidal ideation), or to a ny suicidal behavioral question on the C -SSRS at Screening or 
Day-1 will not be permitted in the study  (see Section 5.2). The “since last visit” version of 
the C -SSRS will be administered at the time points specified in the SoA. The C -SSRS will 
be administered b y stud y site staff who have completed training in its administration.
[IP_ADDRESS].1. Rater Qualifications
For specific rating assessments, only  qualified raters will be allowed to evaluate and/or rate 
participants in this study . The minimum qualifications a rater must meet for each stud y 
rating assessment will be outlined in the guidance document provided to each participating 
site. The level of experience with the target population (or equivalent), specific scale 
experience (or equivalent), and certification required (if applicable) will be listed and used to 

PF-[ADDRESS_1063518] 
of the study . For specifically  defined assessments, rater training and standardization 
exercises may  be conducted, and written and signed documentation will be provided by  [CONTACT_774336]’s certification. In return, each site will be provided written and signed 
documentation outlining each rater’s certification for specific study  assessments. 
Recertification may  be required at periodic intervals during the study . The raters who 
administer specific stud y assessments will be documented in a centralized location and all 
site staff who administer ratings will be verified in the site study  documentation during the 
conduct of the stud y.
[IP_ADDRESS]. Patient Health Questionnaire -9 (Part B only)
The PHQ -9is a 9 item self -report scale for the assessment of de pressive s ymptoms .25The 
PHQ -9 will be completed by  [CONTACT_181877] b y site staff at the pre -defined time 
points outlined in the SoA. A PHQ -9 score of ≥ 15 at Screening and Day  -1 indicates
clinically  significant depression and serves as an exclusion criterion for this study  (see 
Section
5.2).
[IP_ADDRESS].
Referral to a Mental Health Professional
A participant should be referred to a MHP for the following reasons:
Response of “yes” to question 4 or 5, or on any  behavioral question on the C -SSRS.
A score of ≥15 on the PHQ -9.
In the investigator’s judgment, a risk assessment or exclusion is required.
A clinically -qualified MHP is a MHP with appropriate training in the assessment of suicide 
risk, according to local clinical practice standards and regulations, who would normally  
evaluate the risk for suicidal ideation and behavior in a patient.
Participants who have recurrent suicidal ideation or behavior during the study  should be 
discontinued from the study  and treated appropriately .If a stud y participant endorses a [ADDRESS_1063519] active suicidal ideation or behavior on both occasions by  a risk 
assessment conducted b y a qualified MHP, then the pa rticipant should be discontinued from 
the study  and treated appropriatel y.
Participants who meet criteria for referral to a MHP, but refuse evaluation and/or treatment 
by a MHP, must be assessed by  [CONTACT_774337] y.

PF-[ADDRESS_1063520] will be performed after 4 days 
(ie,upon completion of 4 x 24 hours in house), or if they  develop COVID- [ADDRESS_1063521] 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .  
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negativ e pregnancy  test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention s .Pregnancy tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnanc y is otherwise suspected) and at the end of the study.  Pregnancy tests may also be 
repeated if requested b y IRBs/ECs or if required by [CONTACT_427].
8.2.8. Management of Hypoglycemia
While hy poglycemia is not expected in the study  participants, fasting bloo d glucose will be 
measured as part of laboratory  assessment per the SoA. In addition, as a precaution, 
participants will be monitored for the signs and s ymptoms associated with hypogl ycemia.
Any epi[INVESTIGATOR_774322]. For the definition of a hy poglycemic epi[INVESTIGATOR_95461] y 
categorization see Section [IP_ADDRESS] below.
For medical management of hy poglycemia, the investigator may  administer oral 
carboh ydrate, glucagon, or IV glucose according to his or her medical judgment. At a 
minimum however, treat ment or administration of a scheduled meal should be given if 
glucose falls <60 mg/dL for at least [ADDRESS_1063522] 
bother some s ymptoms of hy poglycemia along with glucose values of ≤70 mg/dL.
[IP_ADDRESS]. Definition and Severity of Categorization of Hypoglycemic Adverse Event 
(HAE)
The investigator must assess the glucose values reported by [CONTACT_60653]/local laboratory , as 
well as an y sig ns or s ymptoms reported b y the study  participant.
HAE is defined as oneof the following:27
a.Asymptomatic hy poglycemia: An event not accompanied by  [CONTACT_11017][INVESTIGATOR_107062] a glucose value of <70 mg/dL  (3.9 mmol/L ) using either glucometer 
(fingerstick blood glucose) at the stud y site or sponsor -identified central/local 
laboratory  (blood glucose).

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 66b.Documented s ymptomatic hy poglycemia: An event during which t ypi[INVESTIGATOR_177253] a glucose value of <70 mg/dL (3.9 mmol/L), using 
glucometer at the stud y site or sponsor identified central/local laboratory , and the 
clinical pi[INVESTIGATOR_177255], subcutaneous glucagon, 
or IV glucose.
c.Probable sy mptomatic hypogl ycemia: An event during which sy mptoms of HAE are 
not accompanied b y a glucose determination but was presumabl y caused by a glucose 
concentration of <70 mg/dL  (3.9 mmol/L), and the clinical pi[INVESTIGATOR_219852], subcutaneous glucagon, or IV glucose.
Each epi[INVESTIGATOR_774323] t o severit y. In order to characterize 
the event as severe, all [ADDRESS_1063523] be met:
1. The participant was unable to treat him/herself. Neurologic impairment, and not the 
age of the participant, is the explanation for wh y the participant could not treat 
him/herself and required the assistance of another person.
2.The participant exhibited at least one of the following neurological s ymptoms:
Memory  loss.
Confusion.
Uncontrolled behavior.
Irrational behavior.
Unusual difficulty  in awakening.
Suspected s eizure.
Seizure.
Loss of consciousness.
3.Either:
If blood glucose was measured and was ≤54 mg/dL (2.7 mmol/L) using 
glucometer (or central/local laboratory ) or;
If blood glucose was not measured, the clinical manifestations were reversed by  
[CONTACT_774338], subcutaneous glucagon, or IV glucose.
Events that do not meet all the criteria above for severe HAE are characterized as mild or 
moderate in severity .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 678.2.9. Glucometer Monitoring of Glucose
Monitoring of FSBG using glucometer measurements is not required per protocol, but may  
be obtained if the investigator or participant notes sy mptoms of hy pogly cemia.
If obtained, FSBG readings will be maintained at the CRU in source documents, and only  the 
glucose results from the laboratory  will be reported in the study  database.
If an FSBG result is ≤70 mg/dL, a second FSBG should be obtained to confirm the glucose
value, in addition to a venous sample that will be sent to the clinical laboratory  for 
confirmation. If the value from this second FSBG is also 
≤70 mg/dL , the second value will
be recorded as a h ypogl ycemic AE. FSBG will continue to be monitored until the glucose 
value returns to >70 mg/dL . Samples may  be taken more frequentl y if deemed necessary  by 
[CONTACT_093].
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The i nvestigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess w hether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_1063524] SAE Report Form.
Investigators are not obligated to activel y seek AE or SAE after the participant has concluded 
study  participation . However, if the investigator learns of an y SAE, including a death, at an y 
time after a participant has completed the study , and he/she cons iders the event to be 
reasonabl y related to the study  intervention, the investigator must promptl y report the SAE to 
[COMPANY_007] using the CT SAE Report Form .
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection perio d as described in 
Section 8.3.[ADDRESS_1063525] SAE Report Form immediately  upon 
awareness and under no 
circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1063526] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when de tecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).

PF-[ADDRESS_1063527] be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will c omply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB
s/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  intervention under stud y during pregnancy  or br eastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental exposure during pregnancy : 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 70A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262], inhalation, or skin 
contac t
.
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_240854] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety
 on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collect ed after the start of stud y intervention and until [ADDRESS_1063528] dose of study  intervention .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -
up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome a sa 
follow -up to the initial EDP S upplemental Form. 
In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinic ally possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are conside red SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 71Neonatal deaths that occur within [ADDRESS_1063529] 
to causa lity, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having be en exposed to the study  intervention 
by [CONTACT_19991].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the CT SAE Report Form .  When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is adminis tered in accord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_19994] , which may  or may  not lead to the occurrence of an AE. Such persons 
may include healthcare provider s, famil y members, and other roles that are involved in the 
trial participant’s care.

PF-[ADDRESS_1063530] report occupational exposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness regardless of whether there is an associated SAE.  The information 
must be reported using the CT SAE Report Form.  Since the information does not pertain to a
participant enrolled in the study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Dis ease-Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applicable.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Notapplicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with a n AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 73Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 2 4 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within 24hours on a CT SAE Report 
Form only when associated with an SAE.
Other examples include, but are not limited to:
The administration of expi[INVESTIGATOR_214312] ;
The administration of an incorrect study  intervention ;
The administration of an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by  [CONTACT_774339] t the study  
intervention under question is acceptable for use.
8.4.Treatment of Overdose
For this study , any  dose of 
PF-[ADDRESS_1063531] of general supportive measures.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_44686] m onitor within 24 hours .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -06882961 or 
PF-06865571 (whichever is longer).   
3.Docu ment the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.

PF-[ADDRESS_1063532] dose of 
study intervention if requested by [CONTACT_7195] (determined on a case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by [CONTACT_78256].
8.5. Pharmacokinetics 
Blood samples will be collected for measurement of plasma concentrations of PF-06882961, 
and PF-06865571 (Part B only) as specified in the SoA.
The actual times may change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤[ADDRESS_1063533] time of the collection is noted on the source document and the CRF. This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples collected for measurement of plasma concentrations of PF-06882961,
and PF-[ADDRESS_1063534] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity.  Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented and reported to the sponsor.  
On a case-by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised. Any deviation from the specified sample handling procedure resulting in compromised sample integrity will be considered a protocol deviation.
Any changes in the timing or addition of time points for any planned study assessments must 
be documented and approved by [CONTACT_487229], but will not constitute a protocol amendment.  The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 758.5.1. Plasma for Analysis of PF-06882961
Blood samples of approximately 3 mL, to provide a minimum of approximately 1.2 mL
plasma, will be collected for measurement of plasma concentrations of PF-06882961
as specified in the SoA. Instructions for the collection and handling of 
biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
Samples will be used to evaluate the PK of PF-06882961 . Samples 
collected for analyses of PF-06882961 plasma concentrations may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.
8.5.2. Plasma for Analysis of PF-06865571
Blood samples of approximately 3 mL, to provide a minimum of approximately 1.2 mL
plasma, will be collected for measurement of plasma concentrations of PF-06865571 as specified in the SoA. Instructions for the collection and handling of biological samples will 
be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
Samples will be used to evaluate the PK of PF-06865571. Samples collected for analyses of 
PF-06865571 plasma concentrations may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.
8.6. Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
 
 
 
 CCI
CCICCI
CCI
CCI
CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 76 
 
.
 
.
 
.
  
 
 
 
 
8.8.5. Plasma for Analysis of CP-I (Part B only)
Blood samples of approximately 3 mL, to provide a minimum of approximately 1.2 mL 
plasma, will be collected into appropriately labeled tubes containing K 2EDTA for 
measurement of plasma concentrations of CP-I at times specified in the SoA.  Samples 
collected for measurement of plasma concentrations of CP-I will be analyzed using a validated analytical method in compliance with applicable SOPs.  Instructions for the collection and handling of biological samples will be provided in the laboratory manual.
8.8.6. Plasma for 4- β-hydroxycholesterol/cholesterol Analysis (Part B only)
Blood samples of approximately 4 mL, to provide a minimum of approximately 1.6 mL 
plasma, will be collected into appropriately labeled tubes containing lithium heparin for the analysis of 4- β-hydroxycholesterol and cholesterol at times specified in the SoA.  
Instructions for the collection and handling of biological samples will be provided in the laboratory manual.CCI
CCI
CCI
CCI
CCI
CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 778.9.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor.  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypothe ses
No formal statistical h ypothesis testing will be performed in this study .
9.2.Sample Size Determination
9.2.1. Sample Size for Part A
Approximately  8participants will be enrolled in Part A of this study .The expected widths of 
the 90% confidence intervals with 80% coverage probability  for these comparisons are 
shown in Table [ADDRESS_1063535] of PF- 06865571 on PF -06882961 in Part A –Expected 
Widths of the 90% 
CIs (with 80% Coverage Probability) for Different 
Possible Estimated Effects and Parameters of Interest
Parameter NEstimated Effect
(Test/Reference)AUC 24
Probable
90% CIProbable 
CI Width
AUC 24
(PF-06882961)6100% 74to 135% 61%
150% 111to 203% 92%
200% 148to 270% 122%
8100% 79to 126% 47%
150% 119to 189% 70%
200% 159to 252% 94%
[ZIP_CODE]% 82to 122% 39%
150% 123to 182% 59%
200% 165to 243% 79%

PF-[ADDRESS_1063536] of PF -06865571 on PF -0688296 1PK parameters, t he expected 
widths of the 90% confidence intervals with 80% coverage probability  for these com parisons 
are shown in Table [ADDRESS_1063537] of PF- 06865571 on PF-06882961 in Part B – Expected 
Widths of the 90% CIs (with 80% Coverage Probability) for Different 
Possible Estimated Effects and Parameters of Interest
Parameter NEstimated Effect
(Test/Reference)AUC 24
Probable
90% CIProbable 
CI Width
AUC 24
(PF-06882961)1250% 39% to 65% 26%
75% 58% to 97% 40%
100% 77% to 130% 53%
1450% 40% to 63% 24%
75% 59% to 95% 36%
100% 79% to 127% 48%
1650% 40% to 62% 22%
75% 60% to 93% 33%
100% 81% to 124% 44%
To characterize the effect of PF-06882961 on PF -06865571 PK parameters, the expected 
widths of the 90% confidence intervals with 80% coverage probability  for these comparisons 
are shown in 
Table [ADDRESS_1063538] of PF- 06882961 on PF - 06865571 in Part B – Expected 
Widths of the 90% CIs (with 80% Coverage Probability) for Different 
Possible Estimated Effects and Parameters of Interest
Parameter NEstimated Effect
(Test/Reference)AUC inf
Probable
90% CIProbable 
CI Width
AUC inf
(PF-06865571)[ZIP_CODE]% 90% to 111% 20%
125% 113% to 138% 25%
150% 136% to 166% 30%
200% 181% to 221% 41%

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 7914100% 91% to 110% 18%
125% 114% to 137% 23%
150% 137% to 164% 28%
200% 182% to 219% 37%
[ZIP_CODE]% 92% to 109% 17%
125% 115% to 136% 21%
150% 138% to 163% 25%
200% 184% to 218% 34%
9.3. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set Description
Enrolled/Randomly 
assigned to study intervention“Enrolled" means a participant's agreement to participate in a 
clinical study following completion of the informed consent 
process.  Potential participants who are screened for the 
purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760].
Evaluable All participants assigned to study intervention and who take 
at least [ADDRESS_1063539] 1 dose of PF-06882961 and/or PF-[ADDRESS_1063540] 1 plasma concentration value is reported.
9.4. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.4.1. General Considerations
[IP_ADDRESS]. Derivation of Pharmacokinetic and Endogenous Biomarker ParametersPK parameters for PF-06882961, and PF-06865571 (Part B 
only) will be derived (if data permit) from the plasma concentration-time data using standard noncompartmental methods for Part A and Part B as defined in Table 12 and Table 13 , 
respectively. AUC
12and C maxfor CP-I in Part B will be derived ( Table 13 ).  Plasma 
4-β-hydroxycholesterol/cholesterol at each collection time in Part B will also be calculated.  
Actual PK sampling times will be used in the derivation of PK parameters.CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 80Table 12. Part A – Plasma PK Parameters for PF-[ADDRESS_1063541]-doseLinear/log trapezoidal method
Cmax Maximum plasma concentration Observed directly from data
Tmax Time for C maxObserved directly from data as time of first 
occurrence
Table 13. Part B – Plasma PK Parameters for PF-06882961,  and 
PF-06865571, and Plasma CP-I Parameters
Parameter Compound Day Definition Method of Determination
AUC last PF-[ADDRESS_1063542] quantifiable concentration (C
last).Linear/log trapezoidal method.
AUC inf* PF-[ADDRESS_1063543]+( C last*/k el), where 
Clast* is the predicted plasma 
concentration at the last quantifiable time point estimated from the log-linear regression analysis.
AUC [ADDRESS_1063544]-dose.Linear/log trapezoidal method.
PF-[ADDRESS_1063545] occurrence.PF-06882961 46 and 61
t1/2* PF-06865571 1 and 47 Terminal half-life. Log e(2)/k el, where k el is the 
terminal phase rate constant 
calculated by a linear regression of the log-linear concentration-time curve. CCI
CCI
CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 81Parameter Compound Day Definition Method of Determination
Only those data points judged 
to describe the terminal 
log-linear decline will be used 
in the regression.
CL/F * PF-06865571 1 and 47 Apparent oral clearance. Single Dose = Dose/AUC inf;
Multiple Dose = Dose/AUC 12 PF-06882961 46 and 61
Vz/F * PF-06865571 1 and 47 Apparent oral volume of 
distribution.Single Dose = 
Dose/(AUC inf*kel);
* If data permit.
9.4.2. Statistical Methods for Pharmacokinetic Data
The PK parameters listed in Table 12 and Table 13 will be summarized descriptively for 
Part A and Part B by [CONTACT_774340].
[IP_ADDRESS]. Part A – Statistical Methods for Pharmacokinetic Data
Plasma concentrations of PF-06882961 will be listed and summarized descriptively by [CONTACT_774341] (dosing alone versus co-administration or dose, as applicable).  Individual participant and median profiles of the concentration-time data will be plotted by [CONTACT_3148].  For summary statistics and median plots by [CONTACT_31065], the nominal PK sampling time will be used, for individual participant plots by [CONTACT_5586], the actual PK sampling time will be used for plasma samples.  Median profiles will be presented on both linear-linear and log-linear scales.
Natural log-transformed C
maxand AUC 24of PF-[ADDRESS_1063546]. Estimates of the adjusted mean differences (Test-Reference) and corresponding 90% confidence intervals will be obtained from the models. The adjusted mean differences and 90% confidence intervals for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and90% confidence intervals for the ratios. The reference treatment will be “PF-06882961 20 mg” administered alone, whereas the test treatment will be “PF-06882961 20 mg plus PF-06865571 300 mg BID”.CCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Part B – Statistical Methods for Pharmacokinetic and Endogenous Biomarker
Data
Plasma concentrations of PF-06882961, PF-06865571, and CP-I will be listed 
and summarized descriptively by [CONTACT_774342] (dosing alone versus co-administration or dose, as applicable).  Individual participant and median profiles of the concentration-time data will be plotted by [CONTACT_3148].  For summary statistics and median plots by [CONTACT_31065], the nominal PK sampling time will be used, for individual participant plots by [CONTACT_5586], the actual PK sampling time will be used for plasma samples.  Median profiles will be presented on both linear-linear and log-linear scales.
Natural log-transformed C
max, AUC last, and AUC inf(as data permit) of PF-[ADDRESS_1063547].  Estimates of the adjusted mean differences (Test-Reference) and corresponding 90% confidence intervals will be obtained from the models.  The adjusted mean differences and 90% confidence intervals for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the ratios.  The test treatment will be  “PF-06865571 300 mg plus PF ‑06882961 
200 mg BID” (Period 3), which will be reported separately in comparison to the reference treatment of “PF-06865571 300 mg” (Period 1).
Natural log-transformed AUC
12and C maxof PF‑[ADDRESS_1063548] treatment will be “PF-06865571 300 mg BID plus PF ‑06882961 200 mg BID” (Period 4), which will be 
reported separately in comparison to the reference treatment of “PF ‑06882961 200 mg BID 
administered alone” (Period 2). 
The above and other PK parameters for PF-06865571, and PK parameters for PF-06882961, 
will be separately summarized descriptively by [CONTACT_3148].
The mean of CP-I plasma concentrations on Day 1 will serve as baseline.Change from baseline in AUC
12/[ADDRESS_1063549] the reference will be obtained and corresponding 90% CIs 
will be reported from the models.  The test treatments will be “PF-06882961 120 mg BID” (Day 30) and “PF-06882961 200 mg BID” (Day 46) and reference treatment is “No PF-06882961” (Day 1).  Additionally, AUC
12, AUC 12/12 and C maxfor CP-I will be separately 
summarized descriptive by [CONTACT_3148].
The plasma 4- β-hydroxycholesterol/cholesterol ratios will be summarized descriptively by 
[CONTACT_4475].  Individual subject and median plots will be produced by [CONTACT_4475] (Days 1, 19, 31, and 47).  Percent change of the 4- β-hydroxycholeste rol/cholesterol ratio from baseline will be
summarized descriptively by [CONTACT_4475].CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 839.4.3. Safety Analyses
All safet y anal yses will be performed on the safety population.
AEs, ECGs, BP, 
pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s.  Any  clinical 
laboratory , ECG , BP, and PRabnormalities of potential clinical concern will be described.  
Safety  data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will 
not be required to be reported
, unless otherwise noted.  However, an y untoward findings 
identified on phy sical and/or neurological exam inations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, wil l be considered source data, and will not be required to be 
reported, unless otherwise noted.  Demographic data collected at screening will be reported.
COVID ‑19 specific assessments data will be considered source data and will not be required 
to be report ed.
[IP_ADDRESS]. Electrocardiogram Analyses
For each part, changes from baseline for the ECG parameters QT interval, heart rate, QTcF 
interval, PR interval, and QRS complex will be summarized by  [CONTACT_22841].
The number (%) of participants with maximum postdose Q TcF values and maximum 
increases from baseline in the following categories will be tabulated by  [CONTACT_3148]: 
Safety QTcF Assessment 
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450 ‑480 >480 ‑500 >500
Increase from baseline 30‑60 >60
In addition, an attempt may be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach. If a PK/PD 
relationship is found, the impact of participant factors (covariates) on the relationship 
may be 
examined. If the exposure -QT anal yses is performed, it will be reported separatel y, not as 
part of the CSR .
9.4.4. Other Analyses 
Tertiary /exploratory  analy ses not included in the PK or safet y anal yses outlined above will
be documented in the SAP.

PF-[ADDRESS_1063550] unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating dose-escalation decisions, facilitating PKmodeling, and/or supporting clinical development. 
9.6. Data Monitoring Committee or Other Independent Oversight Committee
This study will not use a DMC. CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 8510. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advert isements) must be reviewed and approved by  [CONTACT_774343]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation o f 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures
;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .  
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participant
s against an y immediate hazar d, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 8610.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study .  The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements o f 21 CFR 50, 
local regulations, ICH guidelines, HI
PAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of da ta related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_140261]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_774344], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D
.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the par ticipant.
Participants who are rescreened are required to sign a new IC D.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 8710.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of partici pant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implem ent appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numer ical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer , the sponsor will protect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations.  In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country i n 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of t he geographical location in which the study is conducted.  These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional s tudies in 
accordance with the format and timelines set forth by  [CONTACT_20009].

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 88www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.   Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample 
CRF s, and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide sci entific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a b iostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and c orrect by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.

PF-[ADDRESS_1063551] permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspecti ons and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and right s of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention peri od without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  ofany regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_488027].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.   Source documents are filed at the investigator site.

PF-[ADDRESS_1063552]-screening visit may be recorded directly on the CRFs 
(ie, for which there is no existing written or electronic record of data) and is to be considered source data:
•Prior and concomitant treatments;
•Non-drug treatments;
•Serious and non-serious adverse events;
•Hypoglyemic adverse events;
•Medication errors;
•Body weight;
•Vital signs (blood pressure and pulse rate);
•Study intervention dosing administration;
•Safety laboratory sample collection;
••PK blood sample collection;
•Participant disposition;
•Withdrawal of consent.
Definition of what constitutes source data can be found in the clinical monitoring plan.
Description of the use of computerized system is documented in the Data Management Plan.10.1.8. Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants.CCI
PF-[ADDRESS_1063553] participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study participant s.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidel ines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  informati on and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presen tation or understanding of 
the study  results.

PF-[ADDRESS_1063554] editorial and ethical practice, the 
sponsor will support publication of multice nter studies only  in their entirety and not as 
individual site data.  In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_774345] l ine with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The cont act information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_774346] . 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact [CONTACT_20016] .  The contact [CONTACT_4662], at a minimum, protocol and study  intervention
identifiers, participant numbers, contact [CONTACT_22850], and contact 
[CONTACT_4664] a contact [CONTACT_214362] a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact [CONTACT_107101] b y investigator staff if they are seeking advice on medical questions or 
problems; however, it should be used only
 in the event that the established communication 
pathway s between the investi gator site and the study  team are not available.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problems that may  
arise durin g the stud y.  For sites other than a [COMPANY_007] CRU, the contact [CONTACT_774347] b y the participant directly , and if a participant calls that number, he or she will be 
directed back to the investigator site.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 9310.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood.  Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  issues.
Table 14. Protocol Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN
Creatinine
eGFRa
Cystatin -C 
eGFR, using CKD -EPI-
Cystatin -Cb
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST
ALT
Total bilirubin
Direct bilirubin
Indirect bilirubin
GGT
Alkaline phosphatase
Uric acid
Albumin
Total proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopycCOVID -[ADDRESS_1063555] (-hCG)d
Urine drug screeninge
Lipid panel:
Total cholesterol
Direct LDL -C
HDL -C
Triglycerides
TSH
Free T4
Calcitonin
Amylase
Lipase
Serum total bile acids
PT/INR/aPTT
At screen ingonly:
HbA1c
FSHf
HIV
HepBsAg
HCVAb
HCV RNA
a.Part A –all safety assessment timepoints and Part B – Screening only.
b.Part B –all safety assessment timepoints beyond Screening.
c.Only if urine dipstick is positive for blood, protein, nitrites ,or leukocyte esterase.
d.Serum -hCG for all WOCBP.
e.The minimum requirement for drug screening includes cocaine, THC, opi[INVESTIGATOR_858] , opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site and study specific).
f.For confirmation of post meno pausal status only.
Investigators must document their review of each laboratory  safet y report.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 94Any remaining serum/plasma from samples collected for clinical safet y laboratory 
measurements at baseline and at all times after dose administration may  be retained and 
stored for the duration of the study .  Upon completion of the study , these retained safet y 
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 
safet y findings.  These data will not be included in the CSR.  Samples to be used for this 
purpose will be shipped to either a [COMPANY_007] -approved BBS facilit y or other designated 
laboratory  and retained for up to 1 year following the completion of the study .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 9510.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urin alysis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator.   Any abnormal laboratory te st 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms
;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or in tensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming in tent. Such overdoses should be reported regardless of 
sequelae.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 96Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whet her “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 97Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, dia rrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_402880]. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathoge nic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
[COMPANY_007] product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are considered unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also 
considered for reporting as product defects, if appropriate.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safet y.  
These requirements are delineated for 3 ty pes of events: (1) SAEs ; (2) nonserious AEs; and 

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 98(3)exposure to the study  intervention under stud y during pregnancy  or breastfeeding, and 
occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE in formation.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)  
Note:  I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Saf ety in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagno sis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 99Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that preven ts normal every day activities. An AE that is assessed 
as severe should not be confused with a nSAE.  Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine th e relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator wi ll also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 100The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined by [CONTACT_456] .  In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of rece ipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 101The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is com pleted at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  repo rted SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].4. Appendix 4: Contraceptive Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100- fold between the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies
for both 
PF-[ADDRESS_1063556] 
1of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per year), preferabl
ywith low user dependency , as described below
during the intervention period and for at least [ADDRESS_1063557] dose of study  
intervention ,which 
corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s) .The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per year), with high user dependency, as described below during the 
intervention period and for at least 28daysafter the last dose of study  intervention, 
which corresponds to the time needed to eliminate any  reproductive safet y risks of the 
study  intervention(s) .  In addition, a second effective method of contraception, as 
described 
below, must be used.  The investigator should evaluate the effectiveness of 
the contraceptive method in relationship to the first dose of study  intervention.
Theinvestigator is responsible for review of medical history , menstrual history , and recent 
sexua l activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fert ility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 103Women in the following categories are notconsidered WOCBP:
1.Prem enopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination , or 
medical history  interview.   The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female :
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
High FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and 
not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt must discontinue 
HRT t o allow confirmation of postmenopausal status before study  enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in cl inical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Intrauterine device .
2.Bilateral tubal occlusion .
3.Vasectomized partner .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 104Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
Sexual abstinence : 
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study
 and the preferred and usual lifest yle of the 
participant.
One of the following effective barrier m ethods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 105 
 
 
 
 
 
 
  
 
 
 
 
 CCI
CCI
CCICCI
CCI
CCI
CCI
CCI
CCI
CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations a re a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks.  The increase in TBili ty pi[INVESTIGATOR_469467]/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  [CONTACT_20024], AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered importa nt medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within th e normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above th e ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline val ues AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_1063558]/AL T and TBili separated by  [CONTACT_726] a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should re turn to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1063559] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase.  Consideration should 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneous anal yses at the time of the 
recognized initial abnormaliti
es to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a 
coformulated product in prescription or over -the-counter medications) , recreational drug, 
suppleme nt (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemicals, should be colle cted.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be r eported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_1063560] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response r ate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 109Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third- degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of po tential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8. Appendix 8: Proposed Chronology of Procedures
For the procedures described below, where multiple procedures are scheduled at the same 
timepoint(s) relative to dosing, the following chronology of events should be adhered to:
•12-lead ECG: obtain prior to vital signs assessment, blood samples, and prior to
dosing (as applicable for pre-dose collection) (see Section 8.2.3 );
•Vital Signs (BP, PR): obtain after 12-lead ECG collection but prior to obtaining blood
samples and prior to dosing (as applicable for pre-dose collection) (see Section 8.2.2 );
•Fasting blood samples [for safety (see Section 8.2.4 , PK (see Section 8.5 ),
 
after assessment of 12-lead ECG and vital signs but prior 
to dosing (as applicable for pre-dose collection);
•For the post-dose PK blood collections (see Section 8.5 ): if collection time coincides
with time of a meal/snack, these blood samples should be collected just prior to themeal/snack;
•Other pre-dose procedures: obtain sample/perform procedure as close as possible to
the scheduled time, but may be obtained before or after blood sample collection(s);
•Dosing: must occur with the morning meal; and where applicable, after any pre-dose
blood sample collection(s).CCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9: Alternative Measures During Public Emergencies
Thealternative study  measures described in this section areto be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -19 pandemic globall y and will become effective for other public emergencies 
only upon written notification from [COMPANY_007]. 
Use of these alternative study  measures are expected to cease upon t he return of business as 
usual circumstances (including the lifting of an y quarantines and travel bans/advisories).
10.9.1. Eligibility
COVID -19testing is mandated for this stud y.A patient should be excluded if he/she has a 
positive test result for COVID -19infection, is known to have as ymptomatic infection, or is 
suspected of having COVID -19.
10.9.2.
Adverse Events and Serious Adverse Events
If a participant has COVID -19 during the study , this should be reported as an AE or SAE and 
appropriate medical intervention provided.  It is recommended that the investigato r consult 
the study  medical monitor regarding how to manager study  intervention , including 
termporary  or permanent discontinuation of study  intervention.

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs absolute
ACC acetyl-CoA carboxylase
ADME absorption, distribution, metabolism, and excretion
AE adverse event
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the plasma concentration-time curve
AUC [ADDRESS_1063561] quantifiable concentration (C
last)
AV atrioventricular
BCRP breast cancer resistance protein
β-hCG beta-human chorionic gonadotropin
BID twice daily
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI [INVESTIGATOR_210119]/F apparent oral clearance
Clast time of the last quantifiable concentration
Cmax maximum plasma concentration
CP-I coproporphyrin I
CO 2 carbon dioxide (bicarbonate)
COVID-[ADDRESS_1063562] European Clinical Trials Database
fm fraction metabolized
FAP final approved protocol
FDA Food and Drug Administration
FSBG fingerstick blood glucose
FSH follicle-stimulating hormone
F/U follow-up
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma-glutamyl transferase
GLP Good Laboratory Practice
GLP-[ADDRESS_1063563]
HIV human immunodeficiency virus
HR heart rateCCI
PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page 114Abbreviation Term
HRT hormone replacement therapy
IB Investigator’s Brochure
IC50 half maximal inhibitory concentration
ICD informed consent document
ICH International Council for Harmonisation
IND Investigational New Drug
INR international normalized ratio
IP investigational product
IPAL investigational product accountability log
IR immediate release
IRB institutional review board
IV intravenous(ly)
K2EDTA dipotassium ethylenediaminetetraacetic acid
kel elimination rate constant
Ki apparent inactivation constant at half-maximal rate of inactivation
kinact maximal inactivation rate
LBBB left bundle branch block
LDL-C low density lipoprotein cholesterol
LFT liver function test
LLN lower limit of normal
MATE multidrug and toxin extrusion protein
mBcrp mouse breast cancer resistance protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR multi-drug resistance
MEN2 multiple endocrine neoplasia syndrome type 2
MHP mental health professional
mRNA messenger ribonucleic acid
msec millisecond
MTD maximum tolerated dose
N/A not applicable
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NCE new chemical entity
NOAEL no observed adverse effect level
OAT organic anion transporter
OATP organic anion transporting polypeptide
OCT organic cation transporte r
PCR polymerase chain reaction
PD pharmacodynamicsCCI
PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page 115Abbreviation Term
P-gp P-glycoprotein
PHQ -9 Patient Health Questionnaire -9
PK pharmacokinetics
PLT platelet
PR pulse rate
PT prothrombin time
PVC premature ventricular contraction/complex
Q8H every  [ADDRESS_1063564]
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
Rac accumulation ratio
RBC red blood cells
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analy sis plan
SoA Schedule of Activities
SOP standard operating procedure
SRSD single reference safet y document
SToD study  team on demand
S[LOCATION_003]R suspected unexpected serious adverse reaction
t½ terminal half -life
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
T4 thyroxine
TBA total bile acids
TBili total bilirubin
TEAE treatment -emergent adverse event
TG triglycerides
THC tetrah ydrocannabinol
TSH thyroid-stimulating hormone
Tmax time for C max
UGT uridine 5' -diphospho -glucuronos yltransferase
ULN upper limit of normal
US [LOCATION_002]
Vz/F apparent oral volume of distribution
WBC white blood cell
WOCBP woman of childbearing potential

PF-[ADDRESS_1063565] JJ, Knuhtsen S,et al. Glucagon -like peptides GLP -1 and GLP -2, 
predicted products of the glucagon gene, are secreted separatel y from pig small intestine 
but not pancreas. Endocrinology  1986;119(4):1467-75.
2. Krey mann B, Williams G, Ghatei MA, et al. Glucagon -
like peptide-1 7- 36: a 
physiological incretin in man. Lancet 1987;2(8571):1300 -
4.
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon- like peptide 1 inhibition of 
gastric empt ying outweighs its insulinotropic effects in healthy  humans. Am J Phy siol 
1997;273(5):E981
-8.
4. Flint A, Raben A, Astrup A, et al. Glucagon -like peptide [ADDRESS_1063566] 1998;101(3):515-20.
5. Armstrong MJ, Gaunt P, Aithal GP, et al. L iraglutide safet y and efficacy  in patients 
with non- alcoholic steatohepatitis (L EAN): a multicentre, double -blind, randomised, 
placebo- controlled phase 2 study . Lancet 2016; 387([ZIP_CODE]):679-90.
6. Yen CL , Stone SJ, Koliwad S, et al. Th ematic review series: gl ycerolipi[INVESTIGATOR_805]. DGAT 
enzy mes and triacy lglycerol biosy nthesis. J L ipid Res 2008; 49(11):2283- 301.
7. Buhman KK, Smith SJ, Stone SJ, et al. DGAT1 is not essential for intestinal 
triacy lglycerol absorption or chy lomicron sy nthesis. J Biol C hem 2002; 
277(28):[ZIP_CODE] -9.
8. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian 
diacy lglycerol acy ltransferase, and related family  members. J Biol Chem 2001; 
276(42):[ZIP_CODE] -6.
9. Yu XX, Murray  SF, Pandey  SK, et al. Antisense oligonucleotide r eduction of DGAT2 
expression improves hepatic steatosis and h yperlipi[INVESTIGATOR_310774]. Hepatology 
2005; 42(2):362 -71.
10. Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacy lglycerol acy ltransferase -2 
(DGAT2), but not DGAT1, with antisense oligonucl eotides reverses diet -induced 
hepatic steatosis and insulin resistance. J Biol Chem 2007; 282(31):[ZIP_CODE]-88.
11. Amin NB, Carvajal -Gonzalez S, Purkal J, et al. Targeting diacy lglycerol acy ltransferase 
2 for the treatment of nonalcoholic steatohepatitis. Sci Tra nsl Med 2019 11: eaav9701.
12. Saxena A, Chidsey  K, Somay aji V. Diacy lglycerol acy ltransferase 2 (DGAT2) inhibitor 
PF-
06865571 reduces liver fat b y MRI -PDFF after 2 weeks in adults with NAFLD. 
Hepatology  2019; 70(1) 1260A.

PF-06882961 and PF-06865571
Protocol C3421038
Final Protocol Amendment 2 , 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Day CP, James OF. Hepatic steatosis: innocent by[CONTACT_774348]? Hepatology  
1998; 27(6):1463 -6.
14. Sany al AJ, Friedman SL , McCullough AJ, et al. Challenges and opportunities in drug 
and biomarker development for nonalcoholic steatohepatitis: findings and 
recommendations from an American Association for the Study  of L iver Diseases -U.S. 
Food and Drug Administration Joint Workshop. Hepatology  2015; 61(4):1392-405.
15. Fazel Y, Koenig AB, Sayiner M, et al. Epi[INVESTIGATOR_774324] -
alcoholic fatt y liver disease. Metab Clin Exp 2016; 65(8):1017-25.
16. LaBrecque D, Abbas Z, Anania F, et al. Nonalcoholic fatty  liver disease and 
nonalcoholic steatohepatitis. I n: WGO Global Guidelines NAFLD/NASH (long 
version). Milwaukee, WI: World Gastroenterology  Organisation; 2012: 29 pages.
17. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epi[INVESTIGATOR_774325] --meta -analytic assessment of prevalence, incidence, and outcomes. 
Hepatology  2016; 64(1):73 -84.
18. Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe live r disease in 
lean patients with nonalcoholic fatty  liver disease: A long -term follow -up study . 
Hepatol Commun 2017; 2(1):48-57.
19. Chalasani N, Younossi Z, L avine JE, et al. The diagnosis and management of 
nonalcoholic fatt y liver disease: practice guidance f rom the American Association for 
the Study  of Liver Diseases. Hepatology 2018; 67(1):328-57.
20. VICTOZA®(liraglutide). [LOCATION_002] Prescribing Information. June 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf 
Accessed 02 Apr 2020.
21. OZEMPIC®(semaglutide). [LOCATION_002] Prescribing Information. January  2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf 
Accessed 02 Apr 2020.
22. TRULICITY®(dulaglutide). [LOCATION_002] Prescribing Information. February  2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf 
Accessed 02 Apr 2020.
23. SAXENDA®(liraglutide). [LOCATION_002] Prescribing Information. March 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011 lbl.pdf 
Accessed 02 Apr 2020 .
24. Posner K, Brown GK, Stanley  B, et al. The Columbia -Suicide Severit y Rating Scale: 
initial validity  and internal consistency  findings from three multisite studies with 
adolescents and adults. Am J Psy chiatry  2011;168(12):1266-77.

PF-06882961 and PF-06865571
Protocol C3421038Final Protocol Amendment 2, 03 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ-9: validity of a brief depression severity 
measure. J Gen Intern Med 2001;16(9):606-13.
26. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception and collection of pregnancy information from female partner: update. Clin Transl Med 2016;5(1):23-37.
27. American Diabetes Association. Standards of medical care in diabetes 2019. Diabetes 
Care. January 2019;42(Suppl 1): S1-S193.
CCI